Apparatus and method for generating dendritic cells

The automated cell culture cartridge system with symmetrical fluid flow design addresses the inefficiencies of traditional dendritic cell generation methods by providing uniform flow and reducing contamination, enabling scalable and sterile production of dendritic cells for clinical use.

JP7584411B2Active Publication Date: 2024-11-15FLASKWORKS LLC
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
JP2021526723
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2018-11-15
Filing Date
2019-11-11
Publication Date
2024-11-15
Estimated Expiration
2039-11-11

AI Technical Summary

Technical Problem

Traditional methods for generating dendritic cells are labor-intensive, prone to contamination, and not scalable, with automated systems facing issues like uneven flow and dead spots in cell culture vessels, limiting their clinical and research applications.

Method used

An automated cell culture cartridge system with geometrically configured zones for symmetrical fluid flow, featuring multiple inlets and a central outlet, which avoids dead areas and allows for continuous perfusion, reducing manual intervention and contamination risks.

Benefits of technology

The system enables efficient, scalable, and sterile generation of dendritic cells with uniform flow, enhancing the production of therapeutically relevant numbers while minimizing contamination and labor, suitable for clinical-scale applications.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007584411000011
    Figure 0007584411000011
  • Figure 0007584411000012
    Figure 0007584411000012
  • Figure 0007584411000013
    Figure 0007584411000013
Patent Text Reader

Abstract

A cell culture cartridge is provided that includes multiple zones geometrically configured to provide symmetric fluid flow within each of the multiple zones to avoid dead regions in the flow within each of the multiple zones. In certain embodiments, the cell culture cartridge includes at least eight inlets, with the inlets located at each corner of the cell culture cartridge. In certain embodiments, the shared outlet is located on the top surface of the cell culture cartridge. The present invention provides an optimal and more efficient approach to the automated generation of dendritic cells (DCs).
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of and priority to U.S. patent application Ser. No. 16 / 192,062, filed Nov. 15, 2018, the contents of which are incorporated herein by reference in their entirety. government support

[0002] This invention was made with Government support under Grant No. 1819306 awarded by the National Science Foundation. The Government has certain rights in this invention. FIELD OF THEINVENTION

[0003] The present invention relates generally to cell culture chambers and methods of use thereof. [Background technology]

[0004] background Cell-based cancer immunotherapy is a method of treating cancer using immune-active cells, including dendritic cells (DCs). Because DCs cannot be harvested in sufficient numbers otherwise, they are typically generated by differentiation of monocytes extracted from peripheral blood. However, generating clinically relevant numbers of monocyte-derived dendritic cells for therapeutic use can be difficult. Conventional generation techniques, such as standard well-plate and T-flask culture, involve laborious processes with many manual steps that expose the cell culture to the external environment and require highly trained technicians.

[0005] Conventional generation techniques have numerous safety and contamination concerns, such as mix-up and misidentification of patient samples, exposure to unknown contamination inside laminar flow hoods (e.g., particulates, and bacteria / fungi resistant to standard sterilization techniques such as 70% ethanol), and accidental exposure of cultures to a spoilage environment. Furthermore, scale-up of manual DC generation techniques is generally not feasible, except by adding more culture vessels to the workflow. Automated systems that continuously perfuse fresh medium into the culture vessel while simultaneously removing depleted medium are an alternative option to conventional manual generation techniques.

[0006] Although automated systems generally have less safety and contamination concerns than conventional technology, automated systems suffer from scale-up and other problems. For example, many commercially available automated systems are not scalable for research or clinical level production of DCs. Also, automated systems suffer from uneven flow or dead spots in flow within cell culture vessels. Dead spots in flow (dead areas) are areas in cell culture vessels where uniform flow is not maintained when fresh medium is provided and depleted medium is removed, thereby affecting the production of DCs. Summary of the Invention [Means for solving the problem]

[0007] Abstract The present invention provides an automated cell culture cartridge and system for the generation of dendritic cells with uniform and symmetric flow within the cell culture cartridge. Aspects of the present invention are achieved by designing a cell cartridge chamber with multiple zones each geometrically configured to provide symmetric fluid flow and avoid dead regions in the flow within the cell culture chamber. The geometric design provides uniform flow and avoids dead regions or dead spots in the flow. In this manner, the present invention provides an optimal and more efficient approach to the automated generation of dendritic cells (DCs).

[0008] In certain embodiments, the cell culture chamber includes a plurality of corners. An inlet is disposed at each of the plurality of corners, and an outlet is disposed at a top surface of the cell culture chamber. The placement of the inlets in the cell culture chamber allows for symmetrical fluid flow channels in the cell culture chamber. In some examples, the cell culture chamber includes an octagon having eight corners, each corner including an inlet. The outlet is disposed at the center of the top surface of the cell culture chamber.

[0009] The cell culture chamber also includes various technical features that allow for the automation of manual processes, dramatically reducing user intervention in the process, thereby greatly reducing the risk of contamination. The cell culture chamber allows culture medium and cytokines to be perfused into the chamber, allowing for more consistent levels to be maintained. Achieving consistent nutrient and cytokine levels is important to ensure efficient cell culture and processing, and therefore predictable and effective scale-up. Furthermore, a vertical flow path is provided for fluids exiting the chamber, which ensures that DCs, antigen-specific T cells and other cells involved in the culture process remain in the chamber during perfusion.

[0010] Furthermore, the present invention includes additional features directed to achieving uniform flow. As an example, the cell culture cartridge further includes one or more posts extending between the bottom surface and the top surface. As another example, the bottom surface includes one or more notches on the periphery of the bottom surface. Some embodiments of the present invention further include one or more stopcocks operably coupled to the cell culture chamber.

[0011] The cell culture chamber of the present invention may be manufactured to include a bottom surface made of a material to which cells adhere. In some embodiments, the cells do not adhere to the bottom surface material. In some embodiments, the bottom surface material is treated with air or oxygen plasma under glow or corona discharge. In some embodiments, the bottom surface material is modified with proteins or polyamino acids, such as fibronectin, laminin, and collagen. In some embodiments, the bottom surface material is modified with proteins or polyamino acids, such as fibronectin, laminin, and collagen. The cell culture chamber is made of any suitable material. In certain examples, the one or more materials are selected from the group consisting of polystyrene and acrylate. In some embodiments of the present invention, the cell culture cartridge is transparent. In some embodiments, the height of the cell culture cartridge is ten times smaller than the maximum length or width dimension or less.

[0012] The cell culture cartridge and system may further include one or more stopcocks. The one or more stopcocks may be operably coupled to the cell culture chamber. When attached to the filter, the stopcocks in the cartridge allow air exchange when the cartridge is seeded with cell solution or harvested. When attached to a Luer-activated transfer valve, the stopcocks allow for aseptic transfer of differentiation medium to fill the inlet bottle and remove waste from the outlet bottle. This setup allows the tubing and cartridge system to remain sterile from setup to harvest without the need to break the sterile seal of the system.

[0013] Furthermore, the present invention provides a completely enclosed and sterile iDC generation system for generating immature DCs (iDCs) at a clinical scale, effectively eliminating the need for multiple well plates (or T-flasks / bags), ensuring a sterile, particulate-free culture system, and reducing technician time to maintain the cell cultures. The present invention is an automated cell culture system for sterilely generating therapeutically relevant numbers of iDCs in a single cell culture cartridge. The system can also further process the iDCs to mature them by addition of maturation reagents and stimulate them by addition of one or more antigens to the cell culture chamber. The cell culture system includes a cell culture cartridge that includes multiple zones that are geometrically configured to provide symmetric fluid flow channels in the cell culture chamber and avoid dead regions in the flow in the cell culture chamber. The cell culture system further includes one or more pumps operably associated with the cell culture chamber. In some embodiments, the peristaltic pump provides continuous perfusion of fresh medium into the culture vessel at a specific flow rate per inlet, e.g., 8 μL / min, along with removal of depleted medium into a waste reservoir. Transfer of fresh medium, removal of exhausted medium, cell seeding, and harvesting of iDCs are performed aseptically.

[0014] In some embodiments, the cell culture system further comprises at least one fluid connector configured to fluidly couple the cell culture chamber with a second container, which may be a second cell culture chamber. For example, the cell culture chambers are configured to fluidly connect with each other to allow cells to be concentrated in a smaller volume if such concentration is desired for maturation and antigen stimulation (also known as pulsing) steps. When the system is utilized to stimulate T cells with DCs, the T cells may be automatically transferred between chambers to allow further culture and expansion of the T cells in the new cell culture chamber. In some embodiments, the transfer occurs by introducing a gas flow into the first cell culture chamber to transfer the supernatant containing the first cell product through the fluid connector to the second cell culture chamber.

[0015] In certain aspects, the cell culture chambers of the exemplary embodiments provide for the expansion and stimulation of T cells using antigen-presenting cells from the same patient to provide a therapeutic T cell product that can recruit the patient's own immune system in a manner that selectively targets the patient's tumor. These cell culture systems and methods greatly reduce the number of manual steps compared to conventional protocols. In this manner, the risk of contamination is greatly reduced and the robustness and reproducibility of the manufacturing technique are greatly increased, both of which are important considerations for the safe and reliable manufacture of therapeutic products such as precisely targetable personalized T cell therapies.

[0016] In other embodiments, the cell culture chamber further comprises one or more fluid reservoirs operably coupled to the one or more pumps, the fluid reservoirs configured to supply media containing nutrients and cytokines to the chamber.

[0017] In some embodiments, the present invention further comprises one or more sensors operably connected to the cell culture cartridge. The one or more sensors may measure any suitable parameter. In an example, the one or more sensors measure one or more parameters selected from the group consisting of pH, dissolved oxygen, total biomass, cell diameter, glucose concentration, lactate concentration and cellular metabolite concentration.

[0018] The cell culture chamber may further include a central processing unit (CPU). The CPU may be communicatively coupled to the one or more sensors and configured to adjust the operating state of one or more pumps as a function of the measured one or more parameters. In embodiments in which a flow-inducing mechanism, such as an electrohydrodynamic mechanism, rather than a pump, is used, the central processing unit may alter the operating state of the flow-inducing mechanism to adjust the rate of flow of the first cell product as a function of the one or more parameters.

[0019] In an embodiment, the central processing unit executes instructions that cause the system to receive first input data including a size of a cell culture chamber. Second input data is then received, the second input data including a first concentration of a first cell type and a second concentration of a second cell type in one or more fluids to be introduced into the cell culture chamber. Based on the first and second inputs, a perfusion rate of a perfusion fluid to be introduced into the cell culture chamber is calculated. The calculated perfusion rate maximizes the likelihood that the first cell type and the second cell type contact each other within the cell culture chamber. The first cell type is a peripheral blood mononuclear cell, and the second cell type is a dendritic cell.

[0020] In an embodiment, the system further includes one or more pumps operably connected to the one or more perfusion fluid reservoirs and to a central processing unit, which controls the perfusion rate of the perfusion fluid by controlling the one or more pumps.

[0021] In certain embodiments, the present invention provides a method of culturing dendritic cells. The method includes providing a cell culture cartridge. The cell culture cartridge includes a plurality of zones geometrically configured to provide symmetrical fluid flow with each of the plurality of zones to avoid dead regions in the flow within each of the plurality of zones. In some embodiments, the cell culture cartridge includes a cell culture chamber including a plurality of corners, an inlet disposed at each of the plurality of corners, and an outlet disposed at a top surface of the cell culture chamber. Fluid flows symmetrically through the cell culture chamber.

[0022] The monocytes are seeded into the cell culture cartridge. The dendritic cells are generated by seeding the monocytes into the cell culture chamber and providing continuous perfusion of medium into the cell culture cartridge via the inlet and removing the depleted medium into a waste reservoir via the outlet. In some embodiments, the method further comprises recovering the dendritic cells, and the recovering the cells comprises cooling the cartridge.

[0023] In an embodiment, the method further comprises transferring the immature dendritic cells to a second cartridge, the second cartridge being smaller than the cell culture cartridge. The immature dendritic cells are matured in the second cartridge and subjected to antigen pulsing. In an embodiment, maturation and antigen pulsing may be performed in the cell cartridge without the use of a second cartridge.

[0024] In some embodiments, the methods of the invention further comprise maturation of the dendritic cells and pulsing the cells with an antigen.

[0025] In certain embodiments, to help maintain a desired environment in and around the cell culture chamber, the chamber is sized and configured to fit within an incubator. In some embodiments, the one or more pumps are located within the incubator. In other embodiments, the one or more pumps are located outside the incubator and operably connected to the cell culture chamber within the incubator.

[0026] In certain aspects, at least a portion of the system includes disposable components, some or all of which may be housed within a non-disposable frame. In other aspects, all components of the system are disposable. Furthermore, in some embodiments, the system includes a sample tracking component for tracking and describing patient material.

[0027] The systems and methods are designed such that any number of additional cartridges or cell culture chambers can be provided, in some embodiments, the system includes two or more cell culture cartridges for generating T cells.

[0028] In certain embodiments, the system of the present invention has the ability to automatically calculate and set a desired perfusion rate of a perfusion fluid given various inputs such as the size of a cell culture chamber and the concentration of two or more cell types including dendritic cells and peripheral blood mononuclear cells. In an exemplary arrangement, a cell culture system is provided that includes one or more cell culture chambers and a central processing unit that causes the system to receive as first input data including the size of the cell culture chamber, receive as second input data including a first concentration of a first cell type and a second concentration of a second cell type in one or more fluids to be introduced into the cell culture chamber, and calculate a perfusion rate of a perfusion fluid to be introduced into the cell culture chamber based on the first and second inputs that maximizes the likelihood that the first and second cell types will contact each other in the cell culture chamber. In certain aspects, the first cell type is peripheral blood mononuclear cells and the second cell type is dendritic cells. [Brief description of the drawings]

[0029] [Figure 1] FIG. 1 shows an embodiment of a cell culture chamber of a cell culture cartridge according to the invention.

[0030] [Diagram 2] FIG. 2 shows a front view of the cell culture cartridge and system.

[0031] [Diagram 3] FIG. 3 shows a top view of the cell culture cartridge and system.

[0032] [Figure 4]FIG. 4 shows a left side view of the cell culture cartridge and system.

[0033] [Diagram 5] FIG. 5 shows a right side view of the cell culture cartridge and system.

[0034] [Figure 6] FIG. 6 illustrates an embodiment of a system 100 of the present invention.

[0035] [Figure 7] FIG. 7 shows an embodiment of the invention having two cartridges.

[0036] [Figure 8] FIG. 8 illustrates an embodiment of the invention showing the transfer from a smaller cartridge to an infusion bag.

[0037] [Figure 9] FIG. 9 illustrates the disposable and non-disposable components of the present invention.

[0038] [Figure 10] FIG. 10 shows an embodiment of the EDEN automated fluidic system.

[0039] [Figure 11] FIG. 11 shows the cell culture cartridge design of the flow channels of the cell culture cartridge.

[0040] [Figure 12] FIG. 12 shows a cell culture cartridge design with a (shared) polystyrene surface at the bottom of the cell culture cartridge on which the cells reside.

[0041] [Figure 13] FIG. 13 shows a cell culture cartridge design of flow lines resulting from perfusion within the cell culture cartridge.

[0042] [Figure 14]FIG. 14 shows the cell culture cartridge design of the gauge pressure resulting from perfusion within the cell culture cartridge.

[0043] [Figure 15] FIG. 15 shows cytokine perfusion into a cell culture cartridge.

[0044] [Figure 16-1] FIG. 16 shows the phenotype of iDCs generated in cell culture cartridges and 6-well plates, differentiated from MOs over 6 days. [Figure 16-2] FIG. 16 shows the phenotype of iDCs generated in cell culture cartridges and 6-well plates, differentiated from MOs over 6 days.

[0045] [Figure 17-1] Figure 17 shows the phenotype of iDCs and mDCs from the cell culture cartridge. iDCs were generated in the cell culture cartridge and then seeded into the cell culture system of the present invention for 1 or 3 days of maturation. The labels at the top of the figure indicate the gates from which the plots are derived. [Figure 17-2] Figure 17 shows the phenotype of iDCs and mDCs from the cell culture cartridge. iDCs were generated in the cell culture cartridge and then seeded into the cell culture system of the present invention for 1 or 3 days of maturation. The labels at the top of the figure indicate the gates from which the plots are derived.

[0046] [Figure 18] FIG. 18 illustrates an exemplary method for producing an immunotherapy product according to an embodiment of the present invention.

[0047] [Figure 19] FIG. 19 illustrates a system of the present invention according to one particular embodiment.

[0048] [Figure 20-1] Figure 20 shows the phenotype of MicroDEN N3 iDCs. Data for experiments N1-N2 are shown in Figures 28 and 30. [Figure 20-2] Figure 20 shows the phenotype of MicroDEN N3 iDCs. Data for experiments N1-N2 are shown in Figures 28 and 30.

[0049] [Figure 21-1] Figure 21 shows the phenotype of N3 iDCs in 6-well plates. Data for experiments N1-N2 are shown in Figures 29 and 31. [Figure 21-2] Figure 21 shows the phenotype of N3 iDCs in 6-well plates. Data for experiments N1-N2 are shown in Figures 29 and 31.

[0050] [Figure 22] FIG. 22 shows differentiation data for iDCs generated in the cell culture system and 6-well plates of the present invention, in particular, the harvested iDCs normalized to the surface area of ​​the cartridge (39.7 cm2) or 6-well plates (9.5 cm2 / well) of the present invention.

[0051] [Figure 23] Figure 23 shows differentiation data for iDCs generated in the cell culture system and 6-well plates of the present invention, specifically the average iDCs harvested normalized to the surface area of ​​the cartridge or 6-well plate of the present invention. Data are presented as the mean ± standard deviation of the experiments shown. Data are tabulated in Tables 1-3.

[0052] [Figure 24] FIG. 24 shows differentiation data for iDCs generated in the cell culture system and 6-well plates of the present invention, in particular, the iDC yield for each experiment at seeding densities of 200k-600k MO / cm2.

[0053] [Diagram 25]Figure 25 shows differentiation data for iDCs generated in the cell culture system and 6-well plates of the present invention, specifically, the average iDC yield for each experiment at seeding densities of 200k-600k MO / cm2. Data are presented as the mean ± standard deviation of the experiments shown. Data are tabulated in Tables 1-3.

[0054] [Figure 26-1] Figure 26 shows proliferation statistics of allogeneic functional assays for iDCs generated in the cell culture system of the present invention or in 6-well plates at differentiation seeding densities of 200k-600k MO / cm2. The legends represent the source of iDCs (cell culture system of the present invention or 6-well plates) and the number of iDCs co-cultured with 1 million allogeneic T cells from a single donor. Tabular data are shown in Tables 4-6. [Figure 26-2] Figure 26 shows proliferation statistics of allogeneic functional assays for iDCs generated in the cell culture system of the present invention or in 6-well plates at differentiation seeding densities of 200k-600k MO / cm2. The legends represent the source of iDCs (cell culture system of the present invention or 6-well plates) and the number of iDCs co-cultured with 1 million allogeneic T cells from a single donor. Tabular data are shown in Tables 4-6. [Figure 26-3] Figure 26 shows proliferation statistics of allogeneic functional assays for iDCs generated in the cell culture system of the present invention or in 6-well plates at differentiation seeding densities of 200k-600k MO / cm2. The legends represent the source of iDCs (cell culture system of the present invention or 6-well plates) and the number of iDCs co-cultured with 1 million allogeneic T cells from a single donor. Tabular data are shown in Tables 4-6.

[0055] [Figure 27-1]Figure 27 shows the proliferation histograms of the allogeneic functional assay for experiment N1. The columns represent the MO seeding density for iDCs generated in the cell culture system of the present invention or in 6-well plates. The rows represent the source of iDCs (cell culture system of the present invention or 6-well plates) and the number of iDCs co-cultured with 1 million allogeneic T cells for 5 days. The green vertical line represents the peak position of the stained unstimulated control, which is also the position of the non-dividing cells. The thicker curves represent the global fit and the thinner curves represent the generation of individual T cells. The histograms for experiments N2-N3 are shown in Figures 32 and 33. The unstimulated T cell controls are shown in Figures 34-36. [Figure 27-2] Figure 27 shows the proliferation histograms of the allogeneic functional assay for experiment N1. The columns represent the MO seeding density for iDCs generated in the cell culture system of the present invention or in 6-well plates. The rows represent the source of iDCs (cell culture system of the present invention or 6-well plates) and the number of iDCs co-cultured with 1 million allogeneic T cells for 5 days. The green vertical line represents the peak position of the stained unstimulated control, which is also the position of the non-dividing cells. The thicker curves represent the global fit and the thinner curves represent the generation of individual T cells. The histograms for experiments N2-N3 are shown in Figures 32 and 33. The unstimulated T cell controls are shown in Figures 34-36. [Figure 27-3] Figure 27 shows the proliferation histograms of the allogeneic functional assay for experiment N1. The columns represent the MO seeding density for iDCs generated in the cell culture system of the present invention or in 6-well plates. The rows represent the source of iDCs (cell culture system of the present invention or 6-well plates) and the number of iDCs co-cultured with 1 million allogeneic T cells for 5 days. The green vertical line represents the peak position of the stained unstimulated control, which is also the position of the non-dividing cells. The thicker curves represent the global fit and the thinner curves represent the generation of individual T cells. The histograms for experiments N2-N3 are shown in Figures 32 and 33. The unstimulated T cell controls are shown in Figures 34-36.

[0056] [Figure 28-1]FIG. 28 shows the phenotype of N1 iDCs in the cell culture system of the present invention. [Figure 28-2] FIG. 28 shows the phenotype of N1 iDCs in the cell culture system of the present invention.

[0057] [Figure 29-1] FIG. 29 shows the phenotype of N1 iDCs in 6-well plates. [Figure 29-2] FIG. 29 shows the phenotype of N1 iDCs in 6-well plates. [Figure 29-3] FIG. 29 shows the phenotype of N1 iDCs in 6-well plates.

[0058] [Figure 30-1] FIG. 30 shows the phenotype of N2 iDCs in the cell culture system of the present invention. [Figure 30-2] FIG. 30 shows the phenotype of N2 iDCs in the cell culture system of the present invention.

[0059] [Figure 31-1] FIG. 31 shows the phenotype of N2 iDCs in 6-well plates. [Figure 31-2] FIG. 31 shows the phenotype of N2 iDCs in 6-well plates.

[0060] [Figure 32-1] Figure 32 shows histograms of experiment N2: allogeneic functional assay. T cell controls are shown in Figures 34-36. [Figure 32-2] Figure 32 shows histograms of experiment N2: allogeneic functional assay. T cell controls are shown in Figures 34-36. [Figure 32-3] Figure 32 shows histograms of experiment N2: allogeneic functional assay. T cell controls are shown in Figures 34-36.

[0061] [Figure 33-1] Figure 33 shows histograms of experiment N3: allogeneic functional assay. T cell controls are shown in Figures 34-36. [Figure 33-2]Figure 33 shows histograms of experiment N3: allogeneic functional assay. T cell controls are shown in Figures 34-36. [Figure 33-3] Figure 33 shows histograms of experiment N3: allogeneic functional assay. T cell controls are shown in Figures 34-36.

[0062] [Diagram 34] Figure 34 shows the T cell control of the allogeneic functional assay for N1. One million T cells (same donor as N1-N3) were cultured for 5 days without iDCs.

[0063] [Diagram 35] Figure 35 shows the T cell control of the allogeneic functional assay for N2. One million T cells (same donor as N1-N3) were cultured for 5 days without iDC.

[0064] [Diagram 36] Figure 36 shows the T cell control of the allogeneic functional assay for N3. One million T cells (same donor as N1-N3) were cultured for 5 days without iDC. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0065] Detailed Description Dendritic cells (DCs) are antigen-presenting cells present both in the circulating blood and in other parts of the body. DCs are a critical component of the immune system. Presentation of antigens by these cells is what drives the mobilization of the immune system against all kinds of infections, as well as the development and persistence of immunological memory. Vaccines specifically designed to target DCs are currently being developed for a wide range of diseases, including cancer, and major attempts are currently underway to develop personalized DC vaccines for infectious diseases, cancer, and transplant rejection. In these disease categories, cell-based therapies using in vitro expanded T cells represent another underexplored area where major progress is currently occurring. DCs are the most potent antigen-presenting cells (APCs), and only APCs are capable of inducing naive T cells. DCs play a key role in the in vivo expansion of T cells and can be used to expand T cells in vitro. From a mechanistic standpoint, DCs are an essential part of the study of human responses important for protective immunity against cancer and infectious diseases, as well as the prevention of autoimmunity and transplant rejection.

[0066] Despite the pivotal role of DCs in both clinical and basic research contexts, methods to obtain these cells from individuals remain under development and inefficient processes. Because DCs are present in very low concentrations (<1%) in blood, these cells must be generated from monocytes, involving a time-consuming and laborious process of static culture and stimulation with cytokines (IL-4 and GM-CSF) contained in the culture medium. In particular, numerous manual steps are necessary to proceed from samples of patient-derived whole blood, leukopheresis products, or peripheral blood mononuclear cells (PBMCs) to sufficient numbers of DCs that can be utilized for vaccine development, T-cell therapy, or mechanistic studies. Scaling, even at the level of one or two conditions, or several tens of samples for studies involving separate blood draws, is cumbersome due to resource requirements in terms of personnel time and number of manual steps. Given the existing and planned uses of these cells on a larger scale, such as in autologous DC-based cell therapies and vaccines, traditional approaches to DC generation pose a significant burden, most importantly in terms of supply and labor costs, as well as the efficiency and reliability of the manufacturing process.

[0067] The present invention provides an automated cell culture cartridge and system for the generation of dendritic cells with uniform and symmetric flow within the cell culture cartridge. A cell culture cartridge is provided that includes a cell culture chamber formed between an upper surface of the cell culture cartridge and a bottom surface of the cell culture cartridge. The cell culture chamber includes multiple zones that are geometrically configured to provide a symmetric fluid flow channel within the cell culture chamber and avoid dead spots or dead areas within the cell culture chamber. A dead spot (dead area) in flow is an area in a cell culture vessel where uniform flow is not maintained when new medium is provided and depleted medium is removed, thereby affecting the generation of DCs. By providing multiple zones within the cell culture cartridge, the present invention provides a symmetric flow channel with no dead spots or dead areas for fluid flow. Additionally, the cell culture chamber of the exemplary embodiment provides features that allow for uniform flow of new medium and removal of depleted medium.

[0068] FIG. 1 shows a top view of a cell culture chamber 1000. The cell culture chamber 1000 is formed between the top and bottom surfaces of a cell culture cartridge. A plurality of fluid flow inlets 1130 are provided in the chamber. The embodiment shown in FIG. 1 includes eight inlets, one of which is indicated by a very thin line 1135. The inlets 1130 are located at each corner 1120 of the cell culture cartridge. The inlets 1130 may be located on the top surface of the cell culture cartridge. One outlet 1150 is located in the center of the cell culture chamber on the top surface of the cell culture cartridge. The chamber 1000 includes a plurality of zones 1160 that are geometrically configured to provide symmetrical fluid flow channels in the cell culture chamber 1000. The notches 1110 are located on the outer periphery of the cell culture chamber to help avoid dead areas or dead spots where uneven fluid flow exists in the cell culture chamber. The struts 1140 extend from the bottom surface to the top surface so that the top surface does not sag or flex creating increased pressure in the chamber. The embodiment shown in FIG. 1 is an exemplary non-limiting embodiment of the present invention. Other non-limiting embodiments may include a different number of inlets. In some example non-limiting embodiments, a cartridge according to the present invention may include 2 inlets, 5 inlets, 10 inlets, 13 inlets, 14 inlets, 20 inlets, 30 inlets, and 100 inlets. Non-limiting embodiments may further include a different number of corners. In some example non-limiting embodiments, a cartridge according to the present invention may include 5 corners, 10 corners, 17 corners, 25 corners, 50 corners, and 100 corners.

[0069] In the present invention, fluid flow symmetry is achieved in a cell culture cartridge. For example, the cartridge is composed of individual zones, each individual zone being the space between two fluid inlets. As shown in FIG. 1, each zone tapers in the middle. shape1110。 In some cases, the number of fluid inlets in the cartridge may be more than eight fluid inlets or less. In a preferred embodiment, the cartridge is divided into eight individual regions or zones with an inlet and a shared outlet (in the middle). This ensures that the entire cartridge is perfused with fresh differentiation medium and no dead areas or spots in the flow are formed. Furthermore, four triangular notches 1110 are located around the periphery to avoid dead areas or spots in the flow occurring in these regions. The cartridge includes eight support posts that support the top surface of the cell culture cartridge, which may be constructed of poly(methyl methacrylate) (PMMA or acrylate). Without the support posts, the top surface of the PMMA would sag and pressure would build up in the cartridge as the medium would support the top of the cartridge.

[0070] The cartridge may be constructed of any suitable material. In some examples, the cartridge is constructed from polystyrene, acrylate, or a combination thereof. As an example, the bottom or bottom surface comprises polystyrene and the top and sides are acrylate. As another example, for high volume manufacturing, the cartridge may be produced entirely from polystyrene.

[0071] In an exemplary embodiment, the bottom surface comprises polystyrene and / or acrylate. One advantage of using polystyrene for the bottom surface on which the culture occurs is that this material plays a useful role in the process of generating dendritic cells from PBMCs. In particular, the polystyrene surface can be used to enrich monocytes from a heterogeneous suspension of PBMCs. This is the first step in the culture process utilized to generate DCs by differentiation of monocytes, for example, by culture in a medium containing IL4 and GM-CSF. Using the same polystyrene surface for dendritic cell generation through one cycle of T cell stimulation is highly valuable from a bioprocessing perspective, as it eliminates the multiple transfer steps that would otherwise be required, thereby enabling a closed system for the manufacture of DC-stimulated therapeutic T cells.

[0072] Furthermore, any suitable material treatment may be performed on the cartridge. In some embodiments, the bottom polystyrene surface may be modified to facilitate cell attachment. For example, the bottom polystyrene surface may be treated with air or oxygen plasma, also known as glow discharge or corona discharge. For example, the bottom polystyrene surface may be modified with proteins or polyamino acids known to facilitate cell attachment, including, but not limited to, fibronectin, laminin, and collagen.

[0073] The bottom is made of 6 and 24 well plates (9.5 cm 2 and 1.9 cm 2 ) or T-flask (25cm 2 ~225cm 2 It is also understood that the surface area may be less than or greater than a conventional well plate (e.g., having a surface area equivalent to standard cell culture dishes and flasks), e.g., about 2.0 cm 2 ~about 500cm 2, for example, about 2.0, 3.0, 4.0, 5.0, 6.0, 7.0, 8.0, 9.0, 10.0, 11.0, 12.0, 13.0, 14.0, 15.0, 16.0, 17.0, 18.0, 19.0, 20.0, 25.0, 30.0, 35.0, 40.0, 45.0, 50.0, 55.0, 60.0, 65.0, 70.0, 75.0, 100.0, 125.0, 150.0, 175.0, 200.0, 400.0, 500.0 cm 2 and any surface area therebetween.

[0074] The surfaces of the cell culture cartridge can be connected to each other using any method known in the art, such as mechanical fastening, adhesive and solvent bonding, and welding. However, considering that the cellular immunotherapy products produced using the systems and methods of the present invention are administered to human patients, regulatory issues may prevent the use of certain or all adhesives in assembling the cell culture chamber. Thus, in certain embodiments, the surfaces are connected without the use of adhesives. In one embodiment, all surfaces of the cell culture chamber, such as the bottom wall, side wall, and top wall, include a first material (e.g., polystyrene) and are connected to each other using ultrasonic welding. It should be understood that the above-mentioned arrangements are only examples, and that other arrangements for connecting the surfaces are also contemplated embodiments of the present invention.

[0075] The height of the cell culture chamber or chambers can vary. For example, but not limited to, examples of cell culture chamber height ranges include any height between 0.5 mm and 100 mm, such as 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 6.0, 7.0, 8.0, 9.0, 10.0, 15.0, 20.0, 25.0, 30.0, 35.0, 40.0, 45.0, 50.0, 55.0, 60.0, 65.0, 70.0, 75.0, 80.0, 85.0, 90.0, 95.0, 100.0 mm or higher, or any height therebetween. In certain embodiments, the chamber height can be comparable to the liquid height in cultures typically performed in 6 and 24 well plates, such as 2-6 mm, with a volume of about 0.8 mL to 6 mL. In other embodiments, the cell culture chamber can be approximately 50 cm 2 The culture surface is large, such as 10 mm to 50 mm.

[0076] In some embodiments of the invention, the cartridge is optically clear or transparent. Such optical transparency, in combination with appropriately separated fluidic ports, allows the user to view the cells at any vertical plane within the cartridge. As shown in Figures 2-5, embodiments of the invention include optically clear or transparent cell culture cartridges.

[0077] Figure 2 shows a front view of the cell culture cartridge and system. Figure 3 shows a top view of the cell culture cartridge and system. Figure 4 shows a left side view of the cell culture cartridge and system. Figure 5 shows a right side view of the cell culture cartridge and system.

[0078] Furthermore, as shown in Figures 2-5, the stopcocks may be installed on the cartridge or on the reservoir bottle. In particular, the stopcocks are installed on specific ports on the cartridge, each serving a specific function. The installation is specific to each function, and work was done to determine the optimal location to ensure the process is successful and the workflow is easy. For example, the front stopcock is for seeding and harvesting, and the Luer-activated valve (LAV) on the top of the stopcock allows a syringe to be connected aseptically. The front right stopcock is for seeding and harvesting (adding cold buffer for washing), and the air inside the cartridge flows out through a filter at this stopcock as the cell solution is seeded into the cartridge. As another example, the rear left stopcock is for harvesting, and the air inside the cartridge flows into the cartridge as the cell solution is removed. The filter attached to the stopcock avoids the buildup of pressure or vacuum in the cartridge as liquid is added to or removed from the cartridge.

[0079] In the present invention, the LAV may be used in the bottle to add and / or remove medium. Traditionally, LAVs are sold and marketed for use in anesthesia and IV lines. Therefore, the use of the LAV for adding or removing medium is a departure from traditional use.

[0080] Computational Fluid Dynamics (CFD) was instrumental in the design of the current EDEN cartridge. In particular, CFD was instrumental in designing the cartridge size, support post placement, and triangular notch placement and size.

[0081] In some embodiments, a perfusion flow rate of 8 μL / min can be maintained. This is the same perfusion rate as cell culture systems such as MicroDEN, so linear scale-up of MicroDEN using the system according to the present invention (EDEN) is likely. Each of the eight subsections of the EDEN cartridge is slightly larger than a single MicroDEN cartridge, so the effect of perfusion on cells should be similar in EDEN as in MicroDEN. Thus, the present invention allows MicroDEN experiments to be easily scaled to EDEN without unknown factors such as different fluid flow rates.

[0082] FIG. 6 shows an embodiment of the system 100 of the present invention. It comprises a peristaltic pump 110. The pump 110 is used to pump fluids to and from the cell culture cartridge 120. The cell culture cartridge 120 has a bottom surface 125 to which the cells adhere. In other embodiments, the cells do not adhere to the bottom surface. The cell culture cartridge 120 has eight fluid inlets 145 located at the corners of the cell culture cartridge 120. One fluid outlet 135 is located in the center of the cell culture cartridge 120. A connecting tube 140 connects the fluid inlets with a differentiation medium reservoir (perfusion source) 180 that contains differentiation medium 182. The differentiation medium reservoir 180 contains the differentiation medium 182 that is pumped to the cell culture cartridge 120. The connecting tube 140 also connects the fluid outlet 135 with a waste reservoir 184. The depleted medium exits the cell culture cartridge 120 through the outlet 135 and is pumped to the waste reservoir 184. The lids 170 and 175 on the differentiation medium reservoir 180 and the waste reservoir 184 are not removable, thereby maintaining a sterile system. In other embodiments, the lids 170 and 175 are removable. Stopcocks and / or LAVs 160 and 165 on the reservoir bottles 180 and 184 allow for aseptic transfer of differentiation medium to fill the inlet bottles and remove waste from the outlet bottles. The console 190 provides design space for placement of the previously mentioned components and also includes a display / user face 192, connections 194 and an on / off switch 196.

[0083] Figure 7 shows an embodiment of the invention having two cartridges. A cell culture cartridge 200 is provided for dendritic cell differentiation from monocytes. A smaller cartridge 220 is provided for maturation and antigen pulsing. In other embodiments, maturation and antigen pulsing may be performed in the main cell culture cartridge without the use of a second cartridge.

[0084] 8 shows an embodiment of the invention having a smaller cartridge 320 for maturation and antigen pulsing. The smaller cartridge 320 is fluidly connected to an infusion bag 330 that contains the final product that travels from the smaller cartridge 320.

[0085] FIG. 9 shows the disposable and non-disposable components of the present invention. The EDEN console 410 is non-disposable and has a length L. In this embodiment, the length L is 14 inches. The smaller cartridge 420 is for maturation and antigen pulsing. The connecting tube 430 connects the inlet and outlet with the reservoir and cartridge. The smaller cartridge 420 and connecting tube 430 are single use and disposable.

[0086] Figure 10 shows an embodiment of the EDEN automated fluidics system, which generates monocytes derived from iDCs while continuously perfusing fresh differentiation medium into the cell culture cartridge.

[0087] Figures 11-14 show cell culture cartridge designs according to embodiments of the invention. Figure 11 shows a cell culture cartridge design of the flow channels of the cell culture cartridge. Figure 12 shows a cell culture cartridge design of the (shared) polystyrene surface at the bottom of the cell culture cartridge where the cells reside. Figure 13 shows a cell culture cartridge design of the flow lines resulting from perfusion within the cell culture cartridge. Figure 14 shows a cell culture cartridge design of the gauge pressure resulting from perfusion within the cell culture cartridge.

[0088] Figure 15 shows cytokine perfusion into a cell culture cartridge. In this embodiment, the cartridge is initially filled with water (medium) without cytokines. Cytokines are perfused into the cartridge at 8 inlet ports at 1.16 mol / m3 (IL-4), and flow through the cartridge is driven by perfusion and exits through an outlet port in the center. In practice, the cell culture cartridge is filled with medium containing cytokines. Data is acquired at the lower or bottom surface of the flow channel, as shown in Figure 12.

[0089] Figure 16 shows the phenotype of iDCs generated in cell culture cartridges and 6-well plates, differentiated from MOs over 6 days. The labels at the top of the figure indicate the gates from which the plots are derived.

[0090] Figure 17 shows the phenotype of iDCs and mDCs from the cell culture cartridge. iDCs were generated in the cell culture cartridge and then seeded into the cell culture system of the present invention for 1 or 3 days of maturation. The labels at the top of the figure indicate the gates from which the plots are derived.

[0091] FIG. 18 shows an exemplary method for generating an immunotherapy product according to an embodiment of the present invention. FIG. 18 shows an overview of a method for the generation of a cell-based immunotherapy product using the system described herein. Briefly, the step of generating a cell therapy product according to certain embodiments of the present invention includes co-culturing stimulated antigen-presenting cells with cells containing T cells in a bioreactor containing a cell culture chamber. A supernatant containing an expanded therapeutic T cell product is generated during the culture. In certain aspects, to generate a sufficient amount of antigen-specific T cells to generate a therapeutic response in a patient, the T cells must undergo additional culture in one or more additional cell culture chambers. To achieve this additional culture, a transfer of the supernatant from the culture chamber in which it was generated to a subsequent cell culture chamber containing a new supply of antigen-presenting cells must occur. The transfer of the supernatant between cell culture chambers may include the introduction of a gas flow into the first cell culture chamber, which transfers the supernatant containing the first cell product through a fluid connector to the new cell culture chamber. Furthermore, during each culture step, a perfusion fluid containing, for example, medium and cytokines, may be perfused into the chamber. In certain embodiments, the perfusion fluid flows through the chamber along a vertical flow path to ensure that the cells remain in the chamber during culture. The only manual step involved in using the system of the present invention is the provision of one or more subsequent cell culture cartridges to the system, each cell culture cartridge including a cell culture chamber, each chamber containing a new batch of antigen peptide-pulsed autologous antigen-presenting cells. The use of gas to facilitate movement may also include manual steps to operate the system setup, but does not destroy the sterility of the system.

[0092] In certain embodiments of the present invention, the cells are harvested. Cell harvesting is typically accomplished by injecting cold buffer into the cartridge. In some embodiments of the present invention, a Peltier element may be incorporated under the cartridge to cool the cartridge to anywhere between about 20°C to about 30°C, which allows for release of the cells without the need to dilute them into a larger volume of fluid.

[0093] In some embodiments, dendritic cells generated in the octagonal cartridge may be moved to a smaller cartridge. When manufacturing dendritic cell-based immunotherapy, immature dendritic cells generated from the differentiation of monocytes (first step) are typically subjected to additional steps (maturation and antigen pulsing). Traditionally, this is accomplished by performing the first step in multiple flasks or wells and then combining the immature dendritic cells into a single flask or well. This type of concentration / consolidation allows for less use of reagents used for expensive maturation and antigen pulsing, and subsequent waste. In the present invention, immature dendritic cells from the octagonal cartridge where the first step is performed are moved to a smaller cartridge for maturation and antigen pulsing. In some embodiments of the present invention, maturation and antigen pulsing are performed in the main cell culture cartridge, and there is no need to use a second cartridge.

[0094] Some embodiments of the invention may use a Luer-actuated valve (LAV) to seed and harvest monocytes (MOs) and immature dendritic cells (iDCs), respectively. This improves the workflow so that the cell solution is not lost during seeding / harvesting. A syringe may be connected to the LAV, such as the MicroDEN system. The syringe may be used as a funnel to add MO solution (for seeding) and cold buffer (for harvesting). The syringe may be used to "pipet" up and down to dislodge and resuspend adherent iDCs, due to the turbulence caused by the "pipetting" action. This "pipetting" up and down is actually the pushing and pulling of the syringe plunger.

[0095] Described herein is an exemplary arrangement in which the systems and methods of the present invention utilize one or more cell culture cartridges, each containing a cell culture chamber configured to be fluidly connected to one another for processing a patient's cellular material to generate an immunotherapy product. It should be understood that the cell culture cartridges are provided in a closed environment in certain embodiments. Scaling up of this exemplary embodiment is within the knowledge of one of ordinary skill in the art by adding modules (e.g., cell culture cartridges) to allow for serial and / or parallel processing. One of ordinary skill in the art will also recognize that different or alternative arrangements may be desired based on the product to be generated.

[0096] In certain embodiments, one or more pumps are operably connected to the cell culture chamber for perfusing the cell culture chamber with a perfusion medium. The perfusion medium includes any suitable medium. In some embodiments, the perfusion medium is a differentiation medium. The cell culture cartridge may also include one or more fluid reservoirs. The fluid reservoir is in fluid communication with the cell culture chamber and may be operably connected to one or more pumps. It also includes one or more tubes for connecting the fluid reservoir to the pump and the cell culture chamber. In certain aspects, the one or more pumps are configured to pump the fluid from the fluid reservoir, through the cell culture chamber, and to a waste collection reservoir. In embodiments, the fluid moves from the fluid reservoir through the tube to the pump and into the cell culture chamber via the inlet, back into the cell culture chamber via the outlet, and through the tube to the waste collection reservoir.

[0097] In certain embodiments, the fluid reservoirs and / or waste collection reservoirs may each be provided as one or more capped bottles either contained within the cell culture chamber or fluidly connected to the chamber. Each reservoir includes an inlet port and an outlet port, or an outlet port and a vent fluidly connected to the inlet of one or more cell culture chambers. In certain aspects, for example, a luer connector and a silicone gasket cut to fit around the luer connector may be used to prevent leakage through either or both of the inlets or outlets.

[0098] In certain embodiments, the cell culture cartridge or cartridges are sized and configured to fit within an incubator as the process takes place within the incubator. Conditions within the incubator include maintaining a temperature of 37°C and a relative humidity of 95-100%. Therefore, the materials selected must have the integrity to withstand these conditions, given that materials (including fluids and organisms) tend to grow under such conditions. Furthermore, in some situations, the conditions within the incubator remain stable, and an automatic recording of the temperature is capable of having knowledge of temperature fluctuations that correlate with any anomalies in the reactions taking place in the incubator. Thus, any power supply should not alter the environment within the incubator. For example, certain pumps generate heat.

[0099] Thus, in one embodiment, the pump is housed separately from the cell culture cartridge, but is still in operative fluid communication with the cell culture cartridge. In another embodiment, the pump is attached directly to the cell culture cartridge and located within the incubator, but without heat or operatively connected to a heat sink and / or fan to dissipate heat. Regardless of this configuration, the pump is operatively linked to the cell culture cartridge and then to the cell culture chamber. Additional details regarding automated cell culture systems based on perfusion, such as a small-scale culture system for endothelial cell culture with on-board reagent storage and perfusion enabled by an on-board disposable peristaltic pump and a large-scale culture system for the generation of dendritic cells from monocytes using a chamber with a polystyrene bottom, can be found in International Patent Application Nos. PCT / US2016 / 040042 and PCT / US2016 / 60701, both of which are incorporated herein by reference in their entirety.

[0100] The system may also include a heater to control the temperature of the cell culture reservoir, and optionally a fluid reservoir. In such a configuration, an incubator is not required and the system may operate autonomously with only a power source. If the system lacks a heater, it may operate inside a cell culture incubator. Some embodiments of the invention include a carbon dioxide (CO2) environment for the media buffer.

[0101] In yet another aspect, the cell culture chamber includes one or more sensors (not shown) operably linked to the cell culture chamber. The sensor may be capable of measuring any suitable parameter. For example, the sensor may be capable of measuring one or more parameters in the cell culture chamber, such as pH, dissolved oxygen, total biomass, cell diameter, glucose concentration, lactate concentration, and cell metabolite concentration. In embodiments in which the system includes multiple cell culture chambers, the one or more sensors may be coupled to one or more cell culture chambers. In certain embodiments, the one or more sensors are coupled to one or more cell culture chambers, but not to all chambers in the system. In other embodiments, the one or more sensors are coupled to all cell culture chambers in the system. In systems with multiple chambers operably linked to one or more sensors, the sensors may be the same in each chamber to which they are coupled, they may all be different, or some sensors may be the same and some may be different. In certain aspects, the one or more sensors are operably linked to a computer system having a central processing unit for performing instructions, such that automatic monitoring and adjustment of parameters is possible. Additional details regarding computer systems for implementing the methods of the present invention using cell culture chambers are provided below.

[0102] In certain embodiments, the cell culture chamber has an inlet and an outlet, both of which can be used to fluidly connect the chamber via a fluid connector with one or more additional containers. In certain embodiments, the additional containers include one or more additional cell culture chambers. The system of the present invention can include any number of cell culture chambers between 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, or up to 100 or more than 100, configured to be fluidly connected with each other in series to generate an immunotherapy product. Alternatively, in addition, one or more cell culture chambers can be arranged in parallel with each other to allow the generation of an immunotherapy product for more than one individual at a time. In a preferred embodiment, the cell culture chambers of the cell culture cartridge are connected via a sterile connection.

[0103] Some or all of the system and its components can be designed using CAD software and then transferred to a laser cutter that allows the plastic to be cut to specific sizes and shapes. Various connections such as inlets and outlets can be produced by laser cutting through holes that can then be manually drilled to provide threads to accept male luer fittings. Fluids can then be introduced into the system by connecting a luer adapter to a blunt dispensing needle with tubing pressed into the blunt needle section. Additional details regarding the construction of the fluid system components can be found in International Patent Application Nos. PCT / US2016 / 040042 and PCT / US2016 / 60701, both of which are incorporated herein by reference in their entirety. Some or all of the system and its components can also be produced using injection molding.

[0104] The above description focuses on the components of the system and various possible configurations. The following description focuses on the process performed using the system of the exemplary embodiment of the present invention. To stimulate and expand antigen-specific T cells, the process begins with co-culture of T cell-containing cells with APCs obtained from the same individual in a cell culture chamber. In a specific embodiment, the T cell-containing cells include peripheral blood mononuclear cells (PBMCs) and the APCs include DCs. The T cell-containing cells and APCs are in a ratio (T cell-containing cells:APC) of about 1000:1 to 1:1000, for example, but not limited to, about 1000:1, 900:1, 800:1, 700:1, 600:1, 500:1, 400:1, 300:1, 200:1, 100:1, 75:1, 50:1, 25:1, 20:1, 15:1, 10:1, 5:1, 4:1, 3:1 , 2:1, 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, 1:10, 1:15, 1:20, 1:50, 1:75; 1:100, 1:200, 1:300, 1:400, 1:500, 1:600, 1:700, 1:800, 1:900, 1:1000, etc., or any ratio therebetween. In one embodiment, a ratio of 10:1 is preferred.

[0105] In order to initiate the stimulation and proliferation of T cells from the interaction of APCs with cells containing T cells, APCs need to be stimulated. This can be done by using one or more stimulating molecules. In certain embodiments, the stimulating molecule is non-tumor specific. In other embodiments, the stimulating molecule is tumor specific. For example, the stimulating molecule can be selected from one or more characteristics of an individual's tumor, such as different antigen peptides. In some embodiments, the stimulating molecule is preferably added only at the beginning of the culture cycle. The stimulating molecule can be added for only about a few minutes, an hour, several hours, or for a longer period. In a preferred embodiment, the stimulating molecule is added for a period of about an hour.

[0106] During the culture of the two cellular materials, a supernatant containing the lighter non-adherent T cells is formed, while the heavier mature APCs (e.g., dendritic cells) adhere to or reside at the bottom surface. In those embodiments in which DCs are used as APCs, the expanded T cells must be extracted from the cell culture chamber by the end of the seventh day, since primary DCs cannot be maintained in culture for more than seven days. Therefore, if additional expansion of T cells is desired, a new supply of dendritic cells is required. It should also be understood that the culture of cells using one batch of dendritic cells can be any period shorter than seven days. For example, the cells can be cultured for any period from less than one minute to seven days, with the culture period depending on the degree of stimulation desired.

[0107] In an exemplary embodiment, after culturing for up to 7 days, the expanded T cells are extracted and transferred to a new cell culture chamber containing new DCs, for example, pulsed with the same antigen peptide used in the first cell culture chamber. The stimulation process can be repeated as many times as necessary to generate a sufficiently large number of cells for a therapeutic dose of T cells. When using a culture surface area equivalent to a typical well plate, the stimulation process is typically repeated four times to generate a sufficient supply of T cells.

[0108] The co-culture of APC and T cells is carried out in culture medium. Examples of culture medium include, but are not limited to, RPMI medium and DC medium sold by CellGenix Inc. (Portsmouth, NH) under the trademark CELLGENIX. Any other suitable culture medium known in the art can be used according to the embodiment of the present invention. Cytokines such as IL-4 and GM-CSF can also be added to the culture medium.

[0109] In one embodiment, perfusion of medium and cytokines can be provided to the cell mixture in the cell culture chamber to aid in the formation of cell-based immunotherapy products. In the plate-based protocol for stimulation of T cells with DCs, a culture volume of approximately 2 mL is maintained from the beginning with injection of cytokines occurring twice within each 7-day stimulation period. The main advantage of perfusion is the ability to maintain a consistent local concentration profile of medium and cytokines, ensuring higher yields and the potential ability to accelerate the process of differentiation of monocytes into DCs compared to the plate-based protocols of the prior art. However, the combination of adherent (DC) and non-adherent (T cell) types, together with the high sensitivity of DCs to mechanical forces, poses challenges for the stimulation and proliferation of antigen-specific T cells, especially with regard to the fluid flow through the cell culture chamber. Therefore, in these embodiments where medium and cytokines are provided by perfusion, the system of the present invention must be able to supply nutrients and cytokines to the cells without removing them from the cell culture cartridge, while also taking into account the shear sensitivity of certain antigen-presenting cells such as DCs. In particular, the systems and methods of some embodiments of the present invention aim to optimize the retention of favorable autocrine / paracrine signals for T cell proliferation while restoring growth factors and maintaining minimal physical stimulation of DCs. To configure this, both the direction and speed of perfusion flow through the cell culture chamber must be taken into account. For example, some embodiments of the present invention may include media flow configurations other than unidirectional flow, such as countercurrent media flow configurations.

[0110] In certain embodiments, the flow rate of the fluid is maintained lower than the sedimentation rate of the antigen-presenting cells. In this way, the antigen-presenting cells are maintained within the culture chamber due to their mass. In other words, the antigen-presenting cells sink toward the bottom of the cell culture chamber and therefore remain in the cell culture chamber.

[0111] In other aspects, the multiple inlets and outlets of the cell culture chamber are arranged such that fluids, such as perfusion fluids, move through the cell culture chamber along a vertical flow path. This configuration helps prevent cells (e.g., both DCs and T cells) from leaving the chamber, especially when flow rates through the chamber are in the range of 2-10 mL / min. The configuration with symmetric inflow and vertical outflow prevents cells from leaving the chamber. As shown at least in FIG. 1, certain embodiments of the cell culture cartridge of the present invention have eight inlets and one vertical outlet.

[0112] 1 as having eight inlets and one vertical outlet, any number of inlets and outlets may be included, so long as fluid flowing out of the chamber exits vertically from the top of the chamber and flows through symmetrical fluid channels within the chamber. For example, a chamber may have any one of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more perfusion fluid inlets and / or outlets.

[0113] In certain embodiments, perfusion of medium occurs at specific times over the period that cells are cultured in any one cell culture chamber, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 times or more each day or week. In other embodiments, medium is perfused continuously during culture. Continuous perfusion helps to maintain a nearly constant culture volume throughout the process.

[0114] In certain aspects, cytokine is injected at one or more points during culture, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 times or more.Alternatively, cytokine can be continuously perfused with culture medium.In these embodiments, continuous perfusion helps to maintain a consistent local concentration profile of cytokine, which can help ensure higher yield compared to static cell culture methods, and has the potential to increase the rate at which T cells are stimulated and proliferate.

[0115] Perfusion parameters can be changed at any time during the culture cycle. Examples of parameters include, but are not limited to, median flow rate, cytokine concentration, and duration of the culture cycle. Each of these parameters can have an impact on the effectiveness of T stimulation. For example, a recent study designing a culture chamber for differentiation of monocytes into DCs used a perfusion rate of 0.1 dyn / cm as described in International Patent Application Nos. PCT / US2016 / 040042 and PCT / US2016 / 60701. 2 We have determined that perfusion rates of medium equivalent to levels of wall shear stress of 100-200 μg / ml can generate DCs that are phenotypically identical to those generated using conventional 6- or 24-well plate-based protocols. Thus, by measuring one or more of the phenotypic and functional measures described above during the culture cycle, the effect of one or more perfusion parameters on efficacy can be monitored, allowing for appropriate adjustments.

[0116] According to certain embodiments, the effectiveness of stimulation can be evaluated at any point during the culture, preferably after 7 days. Both phenotypic and functional measures can be used to evaluate the effectiveness. For example, cell number (fold expansion) can be calculated using the indicated cell counting method. Cell phenotype can be characterized by flow cytometry, including evaluation of antigen specificity by tetramer staining. Functional assays can also be used to evaluate the ability of expanded T cells to recognize antigen-loaded target cells and autologous tumor cells. Results can be evaluated according to the criteria for DC-based T cell stimulation performed in both 24-well plate and G-Rex® formats.

[0117] As described above, because certain APCs, such as dendritic cells, cannot survive in culture for more than seven days, certain embodiments of the present invention include multiple cycles of T cell stimulation using two or more cell culture cartridges in a semi-batch configuration. Each cycle is performed with freshly generated autologous antigen-presenting cells. In certain embodiments, the antigen-presenting cells are pulsed with the same set of antigens for each stimulation cycle. In other embodiments, different sets of antigens are used for one or more stimulation cycles.

[0118] In general, multiple cycles of T cell stimulation include culturing cells in a first cell culture chamber in a manner to generate a supernatant containing a first cell product, providing a second cell culture chamber, and subsequently transferring the supernatant from the first cell culture chamber to the second cell culture chamber by introducing a gas flow into the first cell culture chamber.

[0119] For example, in certain embodiments, a cell culture system is provided that includes a cell culture chamber and a central processing unit that includes a memory that includes instructions executed by the central processing unit. In certain aspects, the instructions cause the system to receive as first input data including a size of the cell culture chamber, receive as second input data including a first concentration of a first cell type and a second concentration of a second cell type in one or more fluids to be introduced into the cell culture chamber, and calculate, based on the first and second inputs, a perfusion rate of a perfusion fluid to be introduced into the cell culture chamber that maximizes the likelihood that the first cell type and the second cell type will contact each other within the cell culture chamber.

[0120] In some embodiments, the system also includes one or more pumps operably linked to the one or more perfusion fluid reservoirs and operably linked to the central processing unit, such that the central processing unit also controls the perfusion rate of the perfusion fluid by controlling the one or more pumps.

[0121] In certain embodiments, the systems and methods of the invention utilize modules (such as, for example, cell culture cartridges containing cell culture chambers and systems thereof) fluidly coupled to one another to process an individual's cellular material to generate an immunotherapy product. The systems or devices of the invention are modular and can be fluidly connected to other similar devices in series (i.e., fluid flows from one device to another) and / or in parallel, and may be configured to be physically stacked on top of one another or physically placed within an associated device such as an incubator. The modular design of the system allows for flexible switching of modules, particularly depending on the desired process to be included within the system.

[0122] Fluidic devices of the invention, including cell culture cartridges containing cell culture chambers, may be provided in either microfluidic embodiments (i.e., one or more channels or chambers therein have dimensions in the range of about 1 μm to about 999 μm), or macrofluidic embodiments (all of the channels or chambers therein have dimensions of about 1 mm or greater).

[0123] Fluidic devices can further include additional fluid channels or compartments, gaskets or seals, mixing zones, valves, pumps, vents, channels for pressurized gas, electrical conductors, reagents, ports and tubes as required by the particular design. They may also include one or more control modules, transmitters, receivers, processors, memory chips, batteries, displays, buttons, controls, motors, pneumatic actuators, antennas, electrical connectors, etc. The devices preferably contain only materials that are non-toxic to mammalian cells and compatible with sterilization by use of alcohol and / or heat or other means, e.g., exposure to gamma radiation or ethylene oxide gas.

[0124] The materials of the equipment are selected for their appropriate chemical compatibility under different temperature and pressure ratings specific to each process. In addition, the selection of pumps implemented in the device, such as syringes, peristaltic pumps, pressure pumps and rotary pumps, range from nL to mL flow rates and pressures from 10 to 10,000 psi depending on the flow and pressure requirements for different functions.

[0125] The systems of the invention may also include one or more sample solution reservoirs, or wells, or other devices for introducing samples into the device at various inlets of the modules in fluid communication with the inlet channels. Reservoirs and wells used to load one or more samples into the fluidic devices of the invention include, but are not limited to, syringes, cartridges, vials, Eppendorf tubes, and cell culture materials (e.g., 96-well plates).

[0126] Where useful, the surface of the device can be made more hydrophilic, for example by exposure to plasma, or can be coated with one or more gels, chemical functional coatings, proteins, antibodies, proteoglycans, glycosaminoglycans, cytokines, or cells. In an embodiment, the cell culture cartridges and systems are located at a centralized site. The equipment is single-use, i.e., patient material is processed in bags, tubes, and cell culture containers that are used only for a single patient cell.

[0127] The fluidic devices of the present invention are preferably free of fluid leakage under operating conditions and capable of sterile operation over periods of days to weeks. The fluidic devices of the present invention also include a sampling mechanism that allows fluid to be removed from the system for testing without introducing new material or contamination into the system.

[0128] In certain aspects, at least a portion of the cell culture system includes disposable components, some or all of which may be housed within a non-disposable frame or console. In other aspects, all components of the system are disposable. Furthermore, in some embodiments, the cell culture system includes a sample tracking component for tracking and describing patient material. In embodiments, the cell culture cartridge and system are located at a centralized site. The equipment is single use, i.e., patient material is processed in bags, tubes, and cell culture containers that are used only for a single patient cell.

[0129] At least one step, and sometimes multiple or all steps, are monitored for product characteristics (e.g., purity and polymorphism) during the manufacturing process using a variety of in-line process analytical tools (PTAs) or miniaturized micro-total analytical systems (micro-TAS).

[0130] As described above, the cell culture system of the present invention can control the direction and flow of fluids and entities within the system. The system of the present invention can use, for example, pressure-driven flow control devices that utilize valves and pumps to manipulate the flow of cells, reagents, etc. in one or more directions and / or into one or more channels of a fluidic device. However, other methods can also be used alone or in combination with pumps and valves, such as electroosmotic flow control devices, electrophoresis and dielectrophoresis (Fulwyer, Science 156, 910 (1974); Li and Harrison, Analytical Chemistry 69, 1564 (1997); Fiedler, et al. Analytical Chemistry 70, 1909-1915 (1998); and U.S. Patent No. 5,656,155, each of which is incorporated herein by reference).

[0131] The systems of the invention may also include or be operatively linked to one or more control systems for controlling the movement of fluids through the system, for monitoring and controlling various parameters within the system, such as temperature, as well as for detecting the presence of cell-based immunotherapy product, the amount of product (direct or indirect), conversion rate, etc. The systems may also be equipped with numerous classes of software, such as advanced real-time process monitoring and control processes that allow for feedback control, as well as processes that allow for integration and scale-up, taking into account reaction and purification results obtained using the system.

[0132] In certain embodiments, the system includes a combination of micro-, milli-, or macrofluidic modules and tubing that are interchangeable in terms of channel dimensions, flow geometry, and interconnections between different modules of the device. Each module and tubing can be designed for a specific function. In one embodiment, all modules in the system are designed for cell culture and T cell stimulation. In other embodiments, modules with the system are designed for different functions such as tissue processing, dendritic cell generation, cell culture, enrichment and / or purification, all integrated for continuous manufacturing of immunotherapy products. Both homogeneous and heterogeneous processes suitable for flow applications are considered. These processes are designed and optimized with respect to the starting materials and the manipulation of conditions such as temperature, pressure, and flow rate so as not to easily clog the system during the flow process.

[0133] The method of scaling up the device is performed by parallel addition of modular reactors or enlargement of modular channels while maintaining a set of dimensionless parameters characteristic of the respective process constants and dimensional parameters within upper and lower limits. During process integration and optimization, process decision variables including temperature, pressure, flow rate and channel dimensions are altered to achieve the desired trade-off between yield, purity and throughput. Throughout the optimization process, the aforementioned set of dimensionless parameters undergoes algebraic optimization with operational constraints. The operational constraints are the lower and upper bounds of the decision variables. The objective function considers the combination of the operational variables of purity, yield and throughput. The dimensionless parameters determine the steady-state quality of the device, but the start-up quality of the device is also useful as it determines the time it takes to reach steady state, and in turn the productivity of the device in the form of delay times and waste. The start-up kinetics are analyzed using both simulations and experiments, and the results are used to optimize the start-up with the implementation of real-time feedback control.

[0134] Aspects of the disclosure described herein, such as the control of fluid movement through the systems described above, as well as the monitoring and control of various parameters, can be performed using any type of computing device, such as a computer or programmable logic controller (PLC), including a processor, e.g., a central processing unit, or any combination of computing devices, each of which performs at least a portion of a process or method. In some embodiments, the systems and methods described herein can be performed on a handheld device, e.g., a smart tablet, a smart phone, or a device specifically made for the system.

[0135] The methods of the present disclosure can be performed using software, hardware, firmware, hardwiring, or any combination thereof. Features that implement functionality can also be physically located in various locations, including being distributed such that parts of the functionality are implemented in different physical locations (e.g., imaging equipment in one room and host workstation in another room, or even in separate buildings, either wirelessly or wired).

[0136] Processors suitable for executing a computer program include, by way of example, both general purpose and special purpose microprocessors, and any one or more processors of any kind of digital computer. Generally, a processor receives instructions and data from a read-only memory or a random access memory, or both. The elements of a computer are a processor for executing instructions and one or more memory devices for storing instructions and data.

[0137] Generally, the computer also includes one or more non-transient mass storage devices for storing data, such as magnetic disks, magneto-optical disks, or optical disks, or is operatively connected to receive data from them, transfer data to them, or both. In some embodiments, the sensors on the system send process data via Bluetooth to a central data collection unit located outside the incubator. In some embodiments, the data is sent directly to the cloud rather than to a physical storage device. Suitable information carriers for embodying computer program instructions and data include, by way of example, all forms of non-volatile memory, including semiconductor memory devices (e.g., EPROM, EEPROM, solid-state drives (SSD), and flash memory devices); magnetic disks (e.g., internal hard disks or removable disks); magneto-optical disks; and optical disks (e.g., CD and DVD disks). The processor and memory may be supplemented by, or integrated with, dedicated logic circuitry.

[0138] To provide for interaction with a user, the subject matter described herein may be implemented in a computer having input or output devices such as I / O devices, e.g., CRT, LCD, LED, or projection devices for presenting information to a user, as well as keyboards and pointing devices (e.g., a mouse or trackball) by which a user can provide input to the computer. Other types of devices can be used to provide interaction with a user as well. For example, feedback provided to the user can be any form of sensory feedback (e.g., visual feedback, auditory feedback, or tactile feedback), and input from the user can be received in any form, including acoustic, speech, or tactile input.

[0139] The subject matter described herein may be implemented in a computer system that includes back-end components (e.g., data servers), middleware components (e.g., application servers), or front-end components (e.g., client computers having a graphical user interface or web browser through which a user can interact with an implementation of the subject matter described herein), or any combination of such back-end, middleware, and front-end components. The components of the system may be interconnected through a network by any form or medium of digital data communication, e.g., a communication network. Examples of communication networks include cellular networks (e.g., 3G or 4G), local area networks (LANs), and wide area networks (WANs), e.g., the Internet.

[0140] The subject matter described herein may be implemented as one or more computer program products, e.g., one or more computer programs tangibly embodied in an information carrier (e.g., a non-transitory computer-readable medium) for execution by or to control the operation of a data processing device (e.g., a programmable processor, a computer, or multiple computers). A computer program (also known as a program, software, software application, app, macro, or code) can be written in any form of programming language, including compiled or interpreted languages ​​(e.g., C, C++, Perl), which may be deployed in any form, including as a stand-alone program or module, a component, a subroutine, or other unit suitable for use in a computing environment. The systems and methods of the present invention may include instructions written in any suitable programming language known in the art, including, but not limited to, C, C++, Perl, Java, ActiveX, HTML5, Visual Basic, or JavaScript.

[0141] A computer program does not necessarily correspond to a file. A program may be stored in a file or part of a file that holds other programs or data, in a single file dedicated to the program in question, or in multiple associated files (e.g., a file that stores one or more modules, subprograms, or portions of code). A computer program may be deployed to be executed on one computer or on multiple computers at one location, or may be distributed across multiple locations and interconnected by a communications network.

[0142] A file may be, for example, a digital file stored on a hard drive, SSD, CD, or other tangible, non-transitory medium. A file may be sent from one device to another over a network (e.g., as packets sent from a server to a client, e.g., through a network interface card, modem, wireless card, etc.).

[0143] Writing a file according to embodiments of the present invention involves transforming a tangible non-transitory computer readable medium, for example by adding, removing or rearranging particles (e.g., by net charge or dipole moment to a pattern of magnetization by a read / write head), which then represents a new collocation of information about a physical phenomenon of interest desired by and useful to a user. In some embodiments, writing involves a physical transformation of matter in the tangible non-transitory computer readable medium (e.g., by certain optical properties that then allow an optical read / write device to read the new collocation of useful information, for example, by burning a CD-ROM). In some embodiments, writing a file involves transforming a physical flash memory device, such as a NAND flash memory device, and storing information by transforming physical elements in an array of memory cells made of floating gate transistors. Methods of writing to a file are well known in the art and can be invoked manually or automatically, for example, by a program or by a save command from software or a write command from a programming language.

[0144] A suitable computing device typically includes mass memory, at least one graphical user interface, at least one display device, and typically includes communication between devices. Mass memory describes a type of computer readable medium, i.e., computer storage media. Computer storage media may include volatile, non-volatile, removable and non-removable media implemented in any method or technology for storage of information, such as computer readable instructions, data structures, program modules or other data. Examples of computer storage media include RAM, ROM, EEPROM, flash memory or other memory technology, CD-ROM, digital versatile disks (DVDs) or other optical storage devices, magnetic cassettes, magnetic tapes, magnetic disk storage devices or other magnetic storage devices, radio frequency identification tags or chips, or any other medium that can be used to store the desired information and that can be accessed by a computing device.

[0145] As a person skilled in the art would recognize as necessary or optimal for carrying out the methods of the present invention, a computer system or machine used in embodiments of the present invention may include one or more processors (e.g., a central processing unit (CPU), a graphics processing unit (GPU), or both), a main memory, and a static memory, in communication with each other via a bus.

[0146] In the exemplary embodiment shown in FIG. 19, the system 600 may include a computer 649 (e.g., a laptop, desktop, or tablet). The computer 649 may be configured to communicate across a network 609. The computer 649 includes one or more processors 659 and memory 663, as well as input / output mechanisms 654. If the method of the present invention employs a client / server architecture, the operation of the method of the present invention may be performed using a server 613, including one or more processors 621 and memory 629, which may obtain data, instructions, etc., or provide results via an interface module 625, or provide results as a file 617. The server 613 may interface across the network 609 through the computer 649 or a terminal 667, or the server 613 may be directly connected to a terminal 667, including one or more processors 675 and memory 679, as well as input / output mechanisms 671.

[0147] System 600 or a machine according to an example embodiment of the invention may further include a video display unit (e.g., a liquid crystal display (LCD) or a cathode ray tube (CRT)) for any of I / O 649, 637, or 671. A computer system or machine according to some embodiments may also include an alphanumeric input device (e.g., a keyboard), a cursor control device (e.g., a mouse), a disk drive unit, a signal generation device (e.g., a speaker), a touch screen, an accelerometer, a microphone, a cellular radio frequency antenna, and a network interface device, which may be, for example, a network interface card (NIC), a Wi-Fi card, or a cellular modem.

[0148] Memory 663, 679 or 629 according to exemplary embodiments of the present invention may include a machine-readable medium on which is stored one or more sets of instructions (e.g., software) embodying any one or more of the methodologies or functions described herein. The software may also reside, completely or at least partially, within the main memory and / or within the processor during its execution by the computer system, with the main memory and processor also constituting machine-readable media. The software may further be transmitted or received across a network via a network interface device. Effect of monocyte seeding density on DC generation

[0149] Dendritic cells (DCs) are becoming increasingly important for research and clinical use, but obtaining sufficient numbers of dendritic cells has become a challenge. The effect of monocyte (MO) seeding density on the generation of monocyte-derived immature DCs (iDCs) was investigated in the perfusion-based culture system of the present invention and in 6-well plates. Cell surface markers and the ability of iDCs to induce proliferation of allogeneic T cells were examined. The data show a strong relationship between iDC phenotype, in particular CD80 / 83 / 86 expression, and T cell proliferation. The cell culture system generating iDCs of the present invention has been studied with 200k-600k MO / cm2 MO seeding density. 2 The results demonstrated that the iDCs generated in the cell culture system of the present invention are better than those generated in well plates in inducing T cell proliferation within a range of seeding densities of 100k. This may be due to the perfusion in the cell culture system of the present invention, which continuously supplies fresh differentiation medium to the differentiating MOs while simultaneously removing the exhausted medium and toxic by-products of cellular respiration. The cell culture system of the present invention generated fewer iDCs on a normalized basis than well plates at lower MO seeding densities, but generated a comparable number of iDCs at a MO seeding density of 600k. This result demonstrates that the cell culture system of the present invention can generate a greater number of iDCs with less manual labor than standard well plate culture, and that the cell culture system generating iDCs of the present invention has a higher ability to induce T cell proliferation.

[0150] Dendritic cells are antigen-presenting cells that are found primarily in solid tissues and play an essential role in activating both adaptive and humoral immune responses. The main function of dendritic cells (DCs) is to identify and capture foreign antigens that pose a threat to the body, process them into smaller peptides, and present these peptides to naive T cells or naive B cells. During antigen presentation, DCs express CD4 + Helper T cells and CD8 + They can activate cytotoxic T cells, as well as naive and memory B cells. In addition, DCs activate natural killer (NK) cells and natural killer T (NKT) cells. Given their ability to induce responses from various immune cells, DCs are attractive targets for therapeutic manipulation. Vaccines containing antigen-loaded DCs for in vivo activation and proliferation of T and B cells have been used for the treatment of infectious diseases and developed to specifically target cancerous cells in several clinical and preclinical trials. Furthermore, DCs play an important role in the emerging field of T cell-based immunotherapy and are used to expand activated T cells in vitro.

[0151] Direct isolation of patient-specific DCs is a challenge because they are present in solid tissues and at very low concentrations (<1%) in human blood. Therefore, DCs are often generated ex vivo from monocyte or stem cell precursors that can be easily isolated from circulating blood. To generate DCs for therapeutic manipulations, the standard method is to isolate peripheral blood mononuclear cells (PBMCs) from peripheral blood leukapheresis products, enrich for CD14+ monocytes (MOs) by plastic adherence, elutriation, or positively selected by magnetic beads, followed by culture with IL-4 and GM-CSF for 5–10 days. Traditionally performed in well plates and T-flasks, this method requires numerous manual manipulations, including replenishing differentiation medium, throughout the culture period. Generated immature DC (iDC) numbers range from approximately 9–15 million and 6–20 million in 6-well plates and T-175 flasks, respectively, while a therapy may require approximately 150 million DCs for a single dose. Scaling up current DC generation techniques to produce adequate numbers of DCs required for clinical immunotherapy is challenging due to the need for numerous manual operations, the large number of well plates / T-flasks required, and significant labor costs. In addition, identifying optimal monocyte seeding density is a substantial challenge associated with scaling up the MO-to-iDC differentiation process, and such information is difficult to elucidate from the literature.

[0152] To overcome the aforementioned deficiencies of manual DC generation, we designed a sealed, automated cell culture system to generate DCs from monocytes with functionality similar to that of iDCs generated in well plates. The cell culture system of the present invention incorporates a closed tubing and cell culture cartridge system that continuously perfuses the cartridge with fresh differentiation medium while simultaneously removing depleted medium and waste products (CO2 and lactate). This setup also reduces the manual handling steps required for initiation and medium replenishment.

[0153] The effect of MO seeding density on iDC yield, phenotype and functionality was investigated. Three seeding densities were studied in the cell culture system of the present invention and in a 6-well plate control: 200,000 MO / cm 2 , 400,000 MO / cm 2 and 600,000 MO / cm 2 As the seeding density of iDCs increased, the iDC yield increased in the cell culture system of the present invention and remained constant in the well plate. The iDC yield in the cell culture system of the present invention was lower than in the well plate at MO seeding densities of 200k and 400k, and was comparable to that in the well plate at MO seeding density of 600k. The iDC phenotype showed a strong dependence on MO seeding density in the cell culture system of the present invention, where iDCs generated from low seeding density induced higher T cell proliferation. The iDCs generated in the cell culture system of the present invention were phenotypically similar to iDCs generated in 6-well plates, thereby supporting previous studies and showing that iDCs generated in the cell culture system of the present invention induce more T cell proliferation than iDCs generated in well plates.

[0154] A total of three identical experiments (N1, N2, N3) were systematically performed to evaluate the performance of the cell culture system of the present invention. Each experiment consisted of three cartridges of the present invention (one cartridge per seeding density) and one or two 6-well plates (two to three wells per seeding density). MOs from a single donor were used for each individual experiment (N1, N2 or N3), requiring a total of three donors for iDC generation. T cells from a fourth donor were used for all allogeneic functional assays. CellGenix GMP DC medium was used as the basal medium for differentiation of MOs to iDCs. The medium was supplemented with 1% penicillin-streptomycin (Gibco 15140122), as well as 350 U / mL of preclinical IL-4 and GM-CSF (CellGenix) for iDC generation.

[0155] Each MO-to-iDC differentiation experiment was 6 days in duration. All experiments were performed in a standard cell culture incubator maintained at 37°C and 5% CO2 with near-saturated humidity. All work was performed under sterile conditions in a laminar flow hood. All cell counts were performed using a Countess II automated cell counter. The cell culture system of the present invention

[0156] Experiments with the cell culture system of the present invention were performed using an automated cell culture system previously described by our group. The polystyrene surface of each cell culture cartridge was treated with O2 plasma for 90 seconds at a power of 50 W. Each cartridge had a surface area of ​​39.7 cm2 of polystyrene and a volume of approximately 12.7 mL. The perfusion rate of differentiation medium was 8.0 μL / min for the entire duration of the experiment. For each experiment, one cartridge of the present invention was used for each seeding density, for a total of three cartridges. This required two pumping devices, since each device holds two cartridges. Previous experiments showed that cells were not removed from the cartridges by the 8.0 μL / min medium perfusion over the course of the experiment, verified by centrifugation of the effluent followed by cell counting.

[0157] At day 0 setup, differentiation medium was added to the inlet bottle to allow for medium perfusion for 3 days. At day 3, when the inlet bottle was almost empty, fresh differentiation medium was added to allow for another 3 days of medium perfusion. Effluent was removed from the outlet bottle at day 3. At day 6, cells were harvested by aspirating the cell medium and washing the cartridge twice with cold DPBS (4°C). Adherent cells remaining after the two DPBS washes were not collected. 6-well plates

[0158] Corning Costar 6-well plates (3516) were used as controls for each experiment. A volume of 2.5 mL of differentiation medium was added to each well. Empty wells were filled with 3.0 mL of DPBS to minimize evaporation. On day 3, 1 mL of fresh differentiation medium was added to each well. On day 6, cells were harvested by aspirating the cell medium and washing each well twice with cold DPBS (4° C.). Adherent cells remaining after the two DPBS washes were not collected. Isolation of PBMCs and MO / T cells

[0159] Four units of whole blood (approximately 470 mL / unit) drawn from normal healthy donors were purchased from StemExpress. Blood was collected by venipuncture and processed the same day. PBMCs were isolated using Ficoll density gradient medium and suspended in CryoStor CS10 cryopreservation medium at a concentration of approximately 50 million PBMCs per mL. Cells were chilled in Mr. Frosty containers at -80°C for 12-24 hours and then transferred to cryogenic LN2 storage for at least one week prior to resuscitation. MO or T cells were enriched from PBMCs using Miltenyi Biotec CD14 or CD3 microbeads and passed through two LS columns. Allogeneic T cell functional assay

[0160] Allogeneic T cell functional assays were performed in Corning Costar 24-well plates (3526) using 0, 200,000 (200k), or 500,000 (500k) iDCs generated in MicroDEN or 6-well plates. Each well contained 1 million allogeneic T cells. CellGenix DCM was used as the base medium and supplemented with 1% penicillin-streptomycin (Gibco 15140122) and 5% human AB serum (Sigma Aldrich H4522). T cells were stained with CellTrace Far Red to assess proliferation. The 24-well plates were covered with foil to protect from light and placed in an incubator (37°C and 5% CO2) for 5 days. Upon harvesting, the cell solution was aspirated and the wells were washed twice with cold DPBS (4°C) to collect the remaining cells. Data was analyzed using FCS Express 6 Flow software. Immunophenotyping

[0161] Flow cytometry was performed on an ACEA Biosciences NovoCyte instrument with 488 nm and 640 nm laser lines and four fluorescence channels. Cells were first stained with Fc Block (BD Biosciences 564220) for 10 minutes after viability staining and before antibody staining. Panel A tested viability (Live / Dead Fixable Green; Invitrogen L34970), CD209 / DC-SIGN (R&D Systems FAB161P100), CD14 (Abcam abl57312), and CD45 (R&D Systems FAB1430A). Panel B tested CD80 (BD Biosciences 557226), CD83 (BD ​​Biosciences 556855), CD86 (BD Biosciences 561128), and CD45. Panel C examined viability, HLA-DR (R&D Systems FAB4869P), CD11c (BD Biosciences 565227), and CD45 (R&D Systems FAB1430A). Panel D examined viability, CD3 (BD ​​Biosciences 555333), CD45 (BD Biosciences 340953), and CellTrace Far Red. Gates were set using CD209 isotype control (R&D Systems IC0041P) and fluorescence-minus-one (FMO) controls for panel A. Data was analyzed using FlowJo software. Flow cytometry gating strategies

[0162] Large cells were gated on an SSC-A / FSC-A plot, followed by single cells on an FSC-A / FSC-H plot. Panel A: Viability / CD45 + Cells were gated and then CD14 / CD209 was plotted to determine CD14 - / CD209 +The percentage of iDCs was determined based on population. Panel B: Lymphocytes were gated on a CD45 histogram and then CD80 / 83 and CD80 / 86 were plotted to determine the iDC phenotype. Panel C: Viability / CD45 + Cells were gated and then HLA-DR / CD11c plotted to determine iDC phenotype. Panel D: Viable cells were gated followed by CD3 / CD45 plot to isolate T cells and then CellTrace Far Red histogram to disentangle T cell proliferation. Three experiments (N1, N2, N3) were performed consecutively (starting on different days), each experiment including one cartridge of the present invention and 2-3 wells of a 6-well plate at each MO seeding density. Viability and immunophenotyping of iDCs were performed by flow cytometry. The number of iDCs generated and iDC yield were calculated by:

[0163] Viable iDCs recovered = [recovered cells] x [viable / CD45+ cells] x [CD209+ / CD14- cells]. iDC yield = recovered viable iDCs ÷ plated MO iDC phenotype

[0164] iDCs generated in our cell culture system and in 6-well plates were phenotypically similar, with subtle differences in CD209 (DC-SIGN) / 80 / 83 / 86 expression depending on MO seeding density. MO-derived iDCs were CD209 + and may have low CD14 expression depending on differentiation conditions. + CD14 - Only cells were considered as iDCs. Figures 20 and 21 show the phenotypic expression for iDCs generated in the cell culture system of the present invention and in 6-well plates, respectively, for experiment N3. Data from N1 and N2 are shown in Figures 28-32.

[0165] The viability of the recovered cells was >90% and comparable between the cell culture system of the present invention and the 6-well plate for experiments N1 and N3. Experiment N2 has a significantly lower viability of approximately 70-90% for the cell culture system of the present invention and approximately 77% for the well plate. There was no correlation between MO seeding density and viability, and all recovered cells were CD45+ leukocytes. CD209 expression of iDCs did not show any dependence on MO seeding density in either the cell culture system of the present invention or the 6-well plate, although iDCs in the cell culture system of the present invention had slightly lower CD209 expression than iDCs in the well plate for experiments N1 and N3 (indicated by a left shift in the fluorescence of CD209). iDCs in experiment N2 had similar CD209 expression in both the cell culture system of the present invention and the well plate.

[0166] A significant population of viable CD45+ cells recovered from the cell culture system of the present invention expresses CD209 - This CD209 - The CD209 population accounted for approximately 20-40% of the cells recovered for experiments N1 / N3 and approximately 2-7% for experiment N2. The 6-well plates contained approximately 2-4% CD209 in all three experiments. - The CD209- population was generated from the 6-well plate and the 200k and 400k MO seeding densities. There was no clear trend between the CD209- population and MO seeding density, but the 200k and 400k MO seeding densities produced fewer CD209- cells than the 600k MO seeding density. The dichotomy between the CD209- cells recovered from the cell culture system of the present invention and the 6-well plate may be due to perfusion in the cell culture system of the present invention during differentiation under the tested conditions. Perfusion may play a role in the delayed kinetics of MO to iDCs, and this population may require a longer differentiation period or higher cytokine concentration to further differentiate into CD209+ iDCs. It is believed that the cell culture system of the present invention generates less differentiated iDCs under certain conditions, and further optimization of the differentiation conditions (i.e., differentiation period, and cytokine concentration, especially IL-4 concentration) in the cell culture system of the present invention is required.

[0167] There is a striking dependence of CD80 / 83 / 86 iDC expression on MO seeding density in the cell culture system of the present invention. iDCs generated in well plates showed relatively constant CD83 / 86 expression, while CD80 expression was highest at a MO seeding density of 200k and decreased with increasing seeding density. All iDCs in both the cell culture system of the present invention and in 6-well plates expressed HLA-DR + and CD11c + In summary, the phenotypic expression of cells harvested from the cell culture system and well plates of the present invention indicates MO-derived iDCs. The iDCs generated in the cell culture system of the present invention are phenotypically similar to those generated in 6-well plates under similar conditions, with minor differences at low MO seeding density. Recovered iDCs

[0168] A direct comparison of the total number of cells recovered between the cell culture system of the present invention and the 6-well plate is not informative since the cell culture system of the present invention had a higher number of seeded MOs, therefore the number of iDCs recovered is normalized to either the surface area of ​​the cell culture system of the present invention or the well plate, and the iDC yield is plotted in Figures 22-25 to allow for direct comparison. There was variability between each experiment (N1-N3) in both the cell culture system of the present invention and the well plate, which is expected when using different donor cells for each experiment. CD209 (DC-SIGN) expression is typically high for iDCs derived from MOs, and the relatively high percentage of CD209- cells generated in the cell culture system of the present invention negatively impacts the number of iDCs recovered. Table 1 shows the experimental data for the iDC generation experiments in the cell culture system of the present invention and in the 6-well plate. Normalized harvested iDCs

[0169] 22 and 23 show the number of iDCs harvested and the average data normalized to the cell culture surface area for each experiment. Both the cell culture system of the present invention and the 6-well plate were cultured in a 1 cm 2 showed a positive correlation between MO seeding density and iDCs harvested on a per cm basis, indicating that more MOs were seeded, and more iDCs were generated. At lower MO seeding densities, the well plates were 1 cm thicker than the cell culture system of the present invention. 2 At a MO seeding density of 600k, both the cell culture system and the well plate of the present invention generated many iDCs per cm 2 Similar numbers of iDCs were generated per well. iDC yield

[0170] Figures 24 and 25 show the iDC yield and average data for each experiment. The cell culture system of the present invention showed a slight positive correlation between MO seeding density and iDC yield when data was averaged across three experiments, however, there was no clear trend within each individual experiment. At 600k MO seeding density, the average iDC yield was similar for both the cell culture system of the present invention and 6-well plate. The 6-well plate had a relatively constant iDC yield with increasing MO seeding density in experiments N1 and N3, however, iDC yield decreased sharply with MO seeding density for experiment N2.

[0171] Well plate N2 showed a trend that was inconsistent with the data generated in this study and other experiments performed in our laboratory. The experimental procedure was exactly the same for this well plate, and we are not aware of the specific problem that caused this outlying trend. The survival rate for experiment N2 was lower than expected, which may be related to the inconsistent iDC yield in this experiment. Interestingly, the phenotype was normal for iDCs generated in these well plates. The average iDC data was plotted with and without the data for 6-well plate N2.

[0172] The cell culture system of the present invention and the 6-well plate have similar iDC yields at the highest seeding density and differ as the seeding density decreases. This indicates that MO seeding density affects the ability of MOs to differentiate into iDCs and that the iDC yield of the cell culture system of the present invention is greatest at higher seeding densities where the yield is similar to the 6-well plate. Furthermore, increasing the MO seeding density above 600k may improve the iDC yield in the cell culture system of the present invention, but this needs to be determined experimentally, as increasing the number of MOs beyond a critical upper limit may negatively affect the differentiation and phenotype of the generated cells. Similarly, the iDC yield at 600k MO seeding density between the cell culture system of the present invention and the well plate indicates that the cell culture system of the present invention produces phenotypically similar iDCs with a similar yield to the well plate. Furthermore, more MOs can be seeded into a single cartridge of the present invention, allowing a greater number of iDCs to be recovered from a single cartridge of the present invention compared to the use of multiple wells / well plates. This ultimately reduces the user's time and minimizes possible errors and contamination. Table 1: Differentiation data for the cell culture system and 6-well plates of the present invention. [Table 1-1] [Table 1-2]

[0173] For 6-well plates, N1 used 3 wells and N2-N3 used 2 wells as shown above in Table 1. The phenotypic data are shown in Figure 20 (cell culture system of the present invention) and Figure 21 (6-well plates). Homologous functional assays

[0174] The ability of the generated iDCs to induce T cell proliferation was examined by an allogeneic functional assay. One million T cells derived from a single donor were co-cultured with 200k or 500k iDCs derived from different MO donors for each experiment (N1, N2, N3). Figure 26 shows the proliferation statistics, and Figure 27 shows the T cell proliferation histogram for experiment N1. The histograms for experiments N2 and N3 are shown in Figures 32 and 33. The proliferation statistics include the division index (average number of cells resulting from each divided cell), the proliferation index (average number of cells compared to the number of initial generation 0 cells), and the division percentage (percentage of cells in the initial population that have not undergone division). By performing this allogeneic functional assay, we attempted to answer two questions: (i) does MO seeding density affect the ability of iDCs to induce T cell proliferation, and (ii) how does the iDCs of the cell proliferation system of the present invention compare with the iDCs of 6-well plates at a given MO seeding density.

[0175] (i) Although there is a clear correlation between the MO seeding density used for iDCs generated in the cell culture system of the present invention and the ability of those iDCs to induce T cell proliferation, MO seeding density appears to have very little effect on the functionality of iDCs generated in well plates. iDCs of the cell culture system of the present invention generated from low MO seeding densities (200k and 400k) show a higher ability to induce T cell proliferation than iDCs generated from a MO seeding density of 600k. T cell proliferation decreases as the MO seeding density used to generate iDCs increases for iDCs of the cell culture system of the present invention, and iDCs of the cell culture system of the present invention have similar functionality to iDCs in well plates when generated at a MO seeding density of 600k.

[0176] (ii) iDCs generated from low MO seeding densities (200k and 400k) in the cell culture system of the present invention are significantly more effective at inducing T cell proliferation than iDCs in 6-well plates. This effect is reduced at high MO seeding densities (600k) where iDCs in the cell culture system of the present invention are slightly more effective than iDCs generated in well plates. These results were consistent for all three experiments.

[0177] As expected, T cell proliferation was higher when 500k iDCs were seeded in a T cell assay compared to 200k iDCs. Data from this assay shows that iDCs generated in the cell culture system of the present invention can induce T cell proliferation without the addition of IL-2, a cytokine normally used for T cell proliferation. iDCs generated in the cell culture system of the present invention also induce higher T cell proliferation compared to iDCs generated in 6-well plates, regardless of MO seeding density. It is important to note that allogeneic T cell assays are the benchmark of the method used to elucidate DC functionality, and the results observed within this study may not extend to specialized syngeneic and other mixed lymphocyte reaction (MLR) functional assays. The relationship between iDC phenotype and T cell proliferation

[0178] To elucidate why iDCs in the cell culture system of the present invention have a higher ability to induce T cell proliferation, the phenotypic data were compared and are shown in Figures 20, 28, and 30 (cell culture system of the present invention) and Figures 21, 29, and 31 (6-well plate). Two important trends were observed: (1) phenotypic differences of iDCs in the cell culture system of the present invention are strongly correlated with T cell proliferation, and (2) there is a very weak to non-existent correlation between phenotype of iDCs in 6-well plate and T cell proliferation.

[0179] (1) The phenotype of iDCs in the cell culture system of the present invention is dependent on MO seeding density. The cell culture system of the present invention produces substantially more CD80 iDCs at lower MO seeding density compared to 600k MO seeding density. + / 83 + / 86 + These CD80 + / 83 + / 86 + iDCs are more differentiated and express CD80 - / 83 - / 86 - Compared to iDCs, they show a phenotype more similar to mature DCs (mDCs). This is possibly a result of the lower ratio of MO per cytokine activity at lower MO seeding density, and these iDCs consequently have a higher ability to induce T cell proliferation. See Table 1 for MO per cytokine activity values. These results suggest that CD80 iDCs with higher functionality are more likely to be expressed in iDCs, even when the primary cells in the sample are negative for these markers. + / 83 + / 86 + Consistent with previous studies involving iDCs, CD80 cells generated in the cell culture system of the present invention + / 83 + / 86 + The presence of iDCs indicates a higher functional capacity.

[0180] (2) The phenotype of iDCs in 6-well plates is independent of MO seeding density. 6-well plates express significantly more CD80 iDCs at all three MO seeding densities. + Mainly CD83 along with the population - / 86 - We generated iDCs from well-plate iDCs. Furthermore, there were no discernible phenotypic differences in well-plate iDCs generated from different MO seeding densities. This suggests that the ratio of MO per cytokine activity does not affect the well-plate iDCs generated within the scope of this study. This is likely because the ratio of MO per cytokine activity is sufficient for any reasonable MO seeding density in static culture. T cell proliferation induced by well-plate iDCs was similar in all conditions studied, since the cytokines available for MO were sufficient for differentiation and no phenotypic differences were observed.

[0181] T cell proliferation was enhanced when a small number of iDCs expressed CD80 + / 83 + / 86 + This is evidenced by the data from the cell culture system of the present invention and the lower T cell proliferation for iDCs in well plates. - / 83 - / 86 - iDCs also express CD80 + / 83 + / 86 + Inhibition of CD209 expression by itself induces T cell proliferation, although to a lesser extent than in the absence of CD209, indicating that CD209 by itself is not sufficient to predict the ability of iDCs to induce T cell proliferation, and that the degree of CD80 / 83 / 86 expression is a better indicator.

[0182] iDCs in the cell culture system of the present invention generated from a MO seeding density of 600k usually induce higher T cell proliferation compared to iDCs in well plates generated under the same conditions (Figure 26). This difference may be a result of perfusion in the cell culture system of the present invention since all other conditions remain equal. Perfusion may affect the kinetics of MO to iDCs. Perfusion in the cell culture system of the present invention also removes medium from the cartridge, which simultaneously removes toxic by-products (CO2 and lactate) dissolved in the medium resulting from cellular respiration. Continuous removal of medium may maintain a lower pH in the cell culture system of the present invention compared to well plates where toxic by-products are not removed. In addition, 1 mL / well of differentiation medium is added to the well plates on day 3 to replenish cytokines. This has an impact on the overall cytokine concentration in the wells that is different from the cell culture system of the present invention. Detailed analysis of cytokine kinetics (e.g., consumption and degradation of cytokines during MO differentiation) along with lactate kinetics and CO2 production is necessary to better understand the specific causes of these results.

[0183] Another factor that may explain the functional differences between the iDCs in the cell culture system of the present invention and in the well plates is the exact nature of the polystyrene surface in contact with the cells. The cell culture system of the present invention used polystyrene treated with O2 plasma, whereas the 6-well plates were tissue culture treated. The type of surface treatment and the exact nature of the polystyrene may affect iDC generation. Despite these differences, the iDCs generated in the cell culture system of the present invention are phenotypically similar to standard well plate cultures and are functionally competent in the expansion of allogeneic T cells. iDC yield Table 2: 1 cm for experiments N1 to N3 2 Recovered iDCs per [Table 2]

[0184] Table 2 shows the results of experiments N1 to N3, particularly the results of the cell culture system of the present invention (39.7 cm 2 ) or 6-well plate (9.5 cm 2 / well) about 1cm 2 The figures show the number of iDCs recovered per 1 cm well plate. 2 Average iDCs recovered per 1000 cells; mean ± standard deviation. Table 3: Mean (± standard deviation) iDC yields for experiments N1-N3 [Table 3] Homologous functional assays

[0185] Tables 4-6 show the proliferation statistics of the allogeneic functional assay for the data in Figure 26. iDCs were co-cultured with 1 million allogeneic T cells for 5 days. Proliferation histograms are shown in Figure 27 (Experiment N1), Figure 32 (Experiment N2) and Figure 33 (Experiment N3). Figures 34-36 show the T cell control of the allogeneic functional assay. Table 4: Homologous functional assay proliferation statistics for experiment N1 [Table 4] Table 5: Homologous functional assay proliferation statistics for experiment N2 [Table 5-1] [Table 5-2] Table 6: Homologous functional assay proliferation statistics for experiment N3 [Table 6]

[0186] The cell culture system of the present invention was developed as a sealed, sterile cell culture system to improve the process of generating dendritic cells from precursor PBMCs or monocytes. This study showed that iDCs generated in the cell culture system of the present invention are phenotypically and functionally equivalent to iDCs generated in standard well plates. The optimal MO seeding density for the cell culture system of the present invention and the effect of seeding density on the ability of iDCs to induce T cell proliferation were systematically determined. The data show a strong correlation between iDC phenotype, especially the degree of CD80 / 83 / 86 iDC expression, and their ability to induce T cell proliferation. Low MO seeding density (200k MO / cm) 2iDCs of the cell culture system of the present invention generated from 100k-150k MO seeding densities showed the highest ability to induce T cell proliferation due to the higher CD80 / 83 / 86 expression of iDCs. iDCs of the cell culture system of the present invention also performed better in allogeneic T cell assays compared to iDCs in 6-well plates within the range of MO seeding densities studied, 200k-600k. Furthermore, while the cell culture system of the present invention generated similar numbers of iDCs as 6-well plates at higher MO seeding densities, the cell culture system of the present invention generated fewer iDCs than 6-well plates at lower MO seeding densities on a normalized basis. The decision to generate iDCs at low or high seeding densities should be carefully considered and depends on the downstream application of the iDCs, considering whether it is more important to generate a higher number of iDCs or to generate iDCs with higher functional capacity. These trade-offs are common in standard static cultures and, naturally, extend to the cell culture system of the present invention. EXAMPLES

[0187] EDEN Cell Culture Cartridges and Fluidic Systems EDEN was developed to generate therapeutically relevant numbers of iDCs in a single cell culture cartridge that was completely sealed and closed to the external environment. Fresh differentiation medium was perfused through the cartridge and depleted medium was removed. iDCs generated in EDEN showed similar phenotypic expression and iDC yields as iDCs generated in 6-well plates. iDCs matured in the cartridge according to the invention showed canonical CD80 / 83 / 86 upregulation and CD209 downregulation. Computational fluid dynamics simulations helped in the design of the EDEN cartridge to ensure that the perfusing medium flowed properly throughout the cartridge and was adequately replenished with cytokines. These results show that EDEN successfully generated approximately 25 million iDCs with an iDC yield of 20-35% in the conditions tested.

[0188] The EDEN system is shown in Figure 10. The EDEN cell culture cartridge was fabricated using an Epilog Zing 16 laser system from commercially available polystyrene and acrylate cut and assembled using 3M adhesive transfer tape. The polystyrene substrate was plasma treated. The cartridge was 383.6 cm 2 It has an internal surface area of ​​100 μm, a volume of 122 mL, and dimensions of 21.0 cm x 21.0 cm x 0.317 mm (length x width x height). Eight inlet ports around the periphery allow fresh differentiation medium to be perfused into the cartridge, and a single outlet port in the center allows depleted medium to be removed from the cartridge.

[0189] The fluidic system consisted of an inlet bottle for fresh differentiation medium, a peristaltic pump, and an outlet bottle to collect the effluent from the cartridge. An Ismatec IPC-N peristaltic pump was used with PharMED BPT tubing to maintain continuous perfusion of fresh differentiation medium at 8.0 μL / min / inlet. Silicone tubing was connected between the peristaltic tubing and the inlet of the cartridge to facilitate gas exchange between the medium and the ambient environment, which was maintained at 37°C and 5% CO2 inside a Thermo Forma incubator. Silicone tubing was also used at the outlet port, where the perfusion flow rate was estimated to be 64 μL / min. The effluent collected in the waste reservoir was centrifuged to determine if cells were washed out of the cartridge by perfusion; no cells were observed in the effluent and the generated iDCs remained inside the cartridge, indicating that the perfusion flow rate was not high enough to resuspend the cells present in the polystyrene substrate. 285 mL of fresh differentiation medium was added to the inlet reservoir at the beginning (day 0) and day 3 to maintain perfusion over 6 days of differentiation. Cells were harvested by collecting the cell solution and washing each well twice with cold DPBS. Adherent cells after the two DPBS washes were not collected. Differentiation medium

[0190] RPMI 1640 (Gibco 11875119) was supplemented with 10% fetal bovine serum (FBS; heat inactivated; MilliporeSigma F2442), 1% penicillin-streptomycin (P / S; Gibco 15140122), 500 U / mL IL-4 (R&D Systems 204IL), and 500 U / mL GM-CSF (R&D Systems 215GM). PBMC isolation and monocyte enrichment

[0191] Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood StemExpress using Ficoll-Paque (GE Healthcare). Whole blood was collected and processed on the same day. Isolated PBMCs were cryopreserved at 50-60 million PBMCs / mL in a CryoStor CS10 and remained cryopreserved for at least 7 days before resuscitation. Monocytes (MOs) were enriched from resuscitated PBMCs using Miltenyi CD14 microbeads and passed through two LS columns to obtain MOs with purity of >95%. Enriched MOs from a single donor were suspended in 122 mL of differentiation medium and seeded onto EDEN cartridges. Each experiment used MOs from a different donor. 6-well plate control

[0192] Corning Costar 6-well plates (3516) were used as static controls for iDC generation. Each well contained 2.5 mL of differentiation medium, and empty wells were filled with 3.0 mL of DPBS. 1 mL of fresh differentiation medium was added to each well on day 3. Cells were harvested by collecting the cell solution and washing each well twice with cold DPBS. Adherent cells after two DPBS washes were not collected. iDC maturation

[0193] Mature, 17.4cm 2Maturation medium was then cultured in a system according to the invention at 40°C for 1 h at 3.5 μL / min perfusion using a small cartridge holding 5.5 mL of maturation medium. The maturation medium consisted of RPMI 1640 supplemented with 10% HI-FBS, 1% P / S, 2 ng / mL IL-1β (BD Biosciences 554602), 1000 U / mL IL-6 (BD Biosciences 550071), 10 ng / mL TNF-α (MilliporeSigma 11088939001), and 1 μg / mL PGE2 (MilliporeSigma P6532). iDCs from the EDEN1 experiment were cultured at 422,200 iDCs / cm. 2 and matured for either 1 or 3 days in an incubator at 37° C. and 5% CO2. Cells were harvested using two cold PBS washes as described in Kozbial, 2018, Automated generation of immature dendritic cells in a single-use system, Journal of Immunological Methods, 457:53-65, which is incorporated by reference in its entirety. Immunophenotyping

[0194] An ACEA Biosciences NovoCyte flow cytometer was used for immunophenotyping of the harvested iDCs. Panel A tested viability (LIVE / DEAD Fixable Green Dead Cell Stain; Invitrogen L34970), CD209 (R&D Systems FAB161P100), CD14 (Abcam abl57312), and CD45 (R&D Systems FAB1430A). Panel B tested CD80 (BD Biosciences 557226), CD83 (BD ​​Biosciences 556855), CD86 (BD Biosciences 561128), and CD45, with viability not included due to the detection limit of the channel. Panel C tested CD80, CD83, CD86, and CD209 (R&D Systems FAB161A). Gates were set using a CD209 isotype control (R&D Systems IC0041P) for panel A, and a fluorescence-minus-one (FMO) control. Flow cytometry gating strategies

[0195] Large cells were gated on SSC-A / FSC-A plot, followed by single cells on FSC-A / FSC-H plot. Panel A: Viable / CD45+ cells were gated, then CD14 / CD209 was plotted to determine the percentage of MO or iDC. Panel B: Lymphocytes were gated on CD45 histogram. Then CD80 / 83 and CD80 / 86 were plotted to determine iDC phenotype. Panel C: DC were gated on CD209 / 80 plot, followed by CD83 / 86 plot on CD209+ / 80+ or ​​CD209+ / 80- cells. iDC generation

[0196] Two iDC generation experiments were performed in which 114.3 and 78.3 million MOs were seeded on EDEN cartridges. After 6 days of differentiation, 25.5 and 24.8 million iDCs were recovered from the respective cartridges. Viable iDCs recovered were calculated by multiplying the total cells recovered by the viable / CD45+ cells, iDCs (CD209+ / 14-). iDC yields (normalized to the number of MOs seeded) were calculated as the number of iDCs recovered divided by the MOs seeded, and were 22.3% and 31.7% for the two EDEN experiments. The 6-well plate controls show that iDC yields were similar to EDEN, with the 6-well plate having a higher yield in experiment 1 and a lower yield in experiment 2.

[0197] Tabular data is shown in Table 7. Phenotypic data is shown in FIG. Table 7: Differentiation data for iDC generation in EDEN and 6-well plates. [Table 7] iDC phenotype

[0198] Immunophenotyping of the generated iDCs is shown in Figure 16. iDCs generated in EDEN and 6-well plates are phenotypically similar after 6 days of differentiation. iDCs are CD209 (DC-SIGN) positive, CD14 negative, and show low expression of CD80 / 83, as expected for MO-derived iDCs. CD86 expression in EDEN2 iDCs was unexpectedly high. This level of expression is typically expected in mature DCs. Dissolved proteins in the fetal bovine serum (FBS) supplemented to the basal medium could be a possible explanation for this irregular expression, since FBS is animal-derived and its composition cannot be tightly controlled. In addition, protein contamination in the cartridge could also explain this high expression, since it was manually assembled in the laboratory. More than 99.7% of the cells were CD45+ in panel B histogram (not shown). This protein expression profile for EDEN-generated iDCs demonstrates the efficacy of EDEN in generating clinically relevant numbers of DCs that are phenotypically similar to static cultures in well plates. iDC maturation

[0199] The iDCs generated in EDEN1 were then matured in the cartridge according to the present invention for either 1 or 3 days. 7.31 million iDCs were seeded in each cartridge (422,200 iDCs / cm2) and 6 million (1-day maturation) and 4.8 million (3-day maturation) mature DCs (mDCs) were recovered with a yield of 81.9% and 66.2%, respectively. The yield was calculated as the number of seeded iDCs divided by the number of recovered mDCs. The number of mDCs was strictly determined by calculating the viable CD45+ / 209+ cells, so that a yield value less than 100% indicates the degree of cell death in each experiment, which was 18.1% (1-day maturation) and 33.8% (3-day maturation) for two sub-experiments.

[0200] The maturation results are tabulated in Table 8. Maturation was performed in small format cartridges. Phenotypic data are shown in Figure 17. In particular, immunophenotyping of mDCs for EDEN1 is shown in Figure 17. CD209 expression was lower for mDCs and decreased with the length of maturation. CD80 expression increased from approximately 11% for iDCs to 48% and 55% for DCs matured for 1 and 3 days, respectively. CD80 expression was generally low in iDCs and upregulated in mDCs, indicating successful maturation. CD83 / 86 expression is clearly dependent on CD80 expression and is shown in the last two rows of Figure 17. CD80+mDCs showed higher expression of CD86 compared to CD80-mDCs, whereas CD83 expression was unchanged. Table 8: Maturation data for iDCs generated with EDEN1 [Table 8] Computational Fluid Dynamics (CFD) Simulation

[0201] CFD simulations in COMSOL Multiphysics were utilized in designing EDEN to understand how the medium flows inside the cartridge. Water at 37°C was used to simulate the differentiation medium. The cartridge was initially filled with plain water without cytokines. In reality, the cartridge is filled with differentiation medium containing cytokines. However, filling the cartridge initially with plain medium (water) allowed the cytokine convection to be visualized. The diffusion of cytokines is extremely low (9216 μm 2 / day), because convection is the driving force behind the cytokine gradient. 3Water containing IL-4 (500 U / mL) from R&D Systems was perfused through the cartridge at 8 μL / min / inlet and exited through the outlet in the center of the cartridge. Cytokine consumption / depletion was not factored into this analysis since we were interested in determining the optimal medium flow of the new differentiation medium. Figure 11 shows the flow channels of the cartridge describing the volume within the cartridge through which the medium flows. The IL-4 cytokine concentration was modeled on the lower polystyrene surface of the flow channel where the cells reside on the cartridge substrate, represented by the purple surface in Figure 12. The flow lines and gauge pressure resulting from the perfusion are shown in Figures 13 and 14, respectively. The IL-4 concentration gradient is shown in Figure 15 for each 24-hour period of perfusion.

[0202] These CFD data were important in the design of the cartridge where the perfused medium was well spread throughout the cartridge. Cytokine concentration and flow line data show that the cartridge is divided between 8 regions with laminar flow of 8 μL / min / inlet. Each region is replenished with fresh differentiation medium after approximately 4 days. Initial CFD simulations showed that dead areas or spots in the flow would form at the locations of the v-shaped notches, so these notches were added to eliminate the dead areas or spots in the flow and facilitate the desired fluid flow. Eight cylindrical supports within the cartridge support the top acrylic surface. Before these were added, slight sagging of the acrylic was observed and the acrylic was supported by the medium within the cartridge, which would cause unnecessary pressure within the cartridge that could affect the cells. Thus, these features, i.e., the notches and supports were added to improve the dead areas or spots in the flow and pressure concerns resulted in the final EDEN cartridge design that adequately assists the perfused medium to flow within the cartridge without causing undesirable pressure gradients. Incorporation by Reference

[0203] References and citations to other documents, such as patents, patent applications, patent publications, journals, books, articles, web content, etc., have been made throughout this disclosure. All such documents are hereby incorporated by reference in their entirety for all purposes. Equal

[0204] While the present invention has been described in conjunction with certain specific embodiments, those skilled in the art, after reading the foregoing specification, may effect various alterations, substitutions of equivalents and other modifications to the compositions and methods described herein. The present invention provides, for example, the following items. (Item 1) a plurality of zones geometrically configured to provide symmetrical fluid flow with each of the plurality of zones to avoid dead regions in the flow within each of the plurality of zones; 1. A cell culture cartridge comprising: (Item 2) 2. The cell culture cartridge of item 1, wherein the cell culture chamber comprises a plurality of corners, an inlet disposed at each corner of the plurality of corners, and an outlet disposed at an upper surface of the cell culture chamber. (Item 3) 3. The cell culture cartridge of item 2, wherein the cell culture chamber comprises an octagon having eight corners, each corner including an inlet. (Item 4) 3. The cell culture cartridge of claim 2, wherein the outlet is centrally located on the top surface of the cell culture chamber. (Item 5) 2. The cell culture cartridge of item 1, wherein the cell culture chamber comprises a bottom surface composed of a material to which cells adhere. (Item 6) 6. The cell culture cartridge according to item 5, wherein the material of the bottom surface is treated with air or oxygen plasma under glow or corona discharge. (Item 7) 6. The cell culture cartridge according to item 5, wherein the material of the bottom surface is modified with proteins or polyamino acids, such as fibronectin, laminin and collagen. (Item 8) 6. The cell culture cartridge of item 5, further comprising one or more support posts extending between the bottom surface and the top surface. (Item 9) 6. The cell culture cartridge of item 5, wherein the bottom surface comprises one or more notches on the periphery of the bottom surface. (Item 10) 2. The cell culture cartridge of item 1, wherein the cell culture cartridge is transparent and made of one or more materials selected from the group consisting of polystyrene and acrylate. (Item 11) 2. The cell culture cartridge of item 1, further comprising one or more stopcocks operably connected to the cell culture chamber. (Item 12) a cell culture cartridge including a plurality of zones geometrically configured to provide symmetric fluid flow with each of the plurality of zones to avoid dead regions in flow within each of the plurality of zones; and One or more pumps operably associated with the cell culture chamber. 1. A cell culture system comprising: (Item 13) 13. The cell culture system of claim 12, wherein the cell culture chamber comprises a plurality of corners, an inlet disposed at each corner of the plurality of corners, and an outlet disposed at a top surface of the cell culture chamber. (Item 14) 14. The cell culture system of claim 13, wherein the cell culture chamber comprises an octagon having eight corners each containing an inlet, the placement of the inlets allowing for symmetric fluid flow channels in the cell culture chamber. (Item 15) 14. The cell culture system according to claim 13, wherein the outlet is centrally located on the top surface of the cell culture chamber. (Item 16) 16. The cell culture system of item 15, wherein the cell culture chamber comprises a bottom surface composed of a material to which cells adhere. (Item 17) 17. The cell culture system of item 16, further comprising one or more supports extending between the bottom surface and the top surface. (Item 18) 17. The cell culture system of claim 16, wherein the bottom surface comprises one or more notches on a periphery of the bottom surface. (Item 19) 13. The cell culture system of item 12, further comprising one or more stopcocks operably connected to the cell culture chamber. (Item 20) 13. The cell culture system of item 12, further comprising at least one fluid connector configured to fluidly connect the cell culture chamber with a second container. (Item 21) 13. The cell culture system of item 12, further comprising one or more sensors operably connected to the cell culture cartridge. (Item 22) 22. The cell culture system of item 21, wherein the one or more sensors measure one or more parameters selected from the group consisting of pH, dissolved oxygen, total biomass, cell diameter, glucose concentration, lactate concentration and cellular metabolite concentration. (Item 23) further comprising a central processing unit, the central processing unit causing the system to receive first input data including a size of the cell culture chamber; receiving second input data comprising a first concentration of a first cell type and a second concentration of a second cell type in one or more fluids introduced into the cell culture chamber; and calculating a perfusion rate of a perfusion fluid to be introduced into the cell culture chamber based on the first and second inputs, which maximizes the likelihood that the first cell type and the second cell type will contact each other within the cell culture chamber. 13. The cell culture system of item 12, which executes instructions. (Item 24) 24. The system of claim 23, wherein the first cell type is a peripheral blood mononuclear cell and the second cell type is a dendritic cell. (Item 25) 24. The system of claim 23, further comprising one or more pumps operably connected to one or more perfusion fluid reservoirs and operably connected to the central processing unit, wherein the central processing unit controls the perfusion rate of the perfusion fluid by controlling the one or more pumps. (Item 26) 1. A method for culturing dendritic cells, comprising: providing a cell culture cartridge including a plurality of zones geometrically configured to provide symmetric fluid flow with each of the plurality of zones to avoid dead regions in flow within each of the plurality of zones; seeding the cell culture cartridge with monocytic cells; and generating dendritic cells by incubating said monocytic cells in a cell culture chamber and providing continuous perfusion of medium into said cell culture cartridge via an inlet and removing depleted medium into a waste reservoir via an outlet. A method comprising: (Item 27) 27. The method of claim 26, further comprising the step of recovering the dendritic cells, wherein the step of recovering the cells comprises cooling the cartridge. (Item 28) 27. The method of claim 26, further comprising the step of transferring immature dendritic cells to a second cartridge, said second cartridge being smaller than said cell culture cartridge. (Item 29) 29. The method of claim 28, wherein the immature dendritic cells are matured and subjected to antigen pulsing in the second cartridge. (Item 30) 27. The method of claim 26, wherein fluid flows symmetrically through the cell culture chamber.

Claims

1. A cell culture cartridge having an octagonal shape, the cell culture cartridge comprising: eight corners, including an inlet located at each corner; an outlet disposed centrally on a top surface of the cell culture cartridge; a bottom surface including one or more notches on a periphery of the bottom surface; and one or more struts extending between said bottom surface and said top surface, said bottom surface and said top surface together at least in part defining a plurality of zones, each zone including one of said corners and one of said inlets, each zone tapering towards said outlet at said center of said top surface, each of said plurality of zones providing symmetrical fluid flow between its respective inlet and said outlet to avoid dead regions in flow within each of said plurality of zones due at least in part to a position of said inlet in each zone relative to said outlet.

1. A cell culture cartridge comprising:

2. The cell culture cartridge of claim 1 , wherein the cell culture cartridge comprises a bottom surface constructed of a material to which cells adhere.

3. The cell culture cartridge of claim 2 , wherein the material of the bottom surface is treated with air or oxygen plasma under glow or corona discharge.

4. The cell culture cartridge of claim 2 , wherein the material of the bottom surface is modified with a protein or polyamino acid, the protein comprising one or more of fibronectin, laminin, and collagen.

5. 10. The cell culture cartridge of claim 1, wherein the cell culture cartridge is transparent and made of one or more materials selected from the group consisting of polystyrene and acrylate.

6. The cell culture cartridge of claim 1 , further comprising one or more stopcocks operably associated with the cell culture cartridge.

7. A cell culture system including a cell culture cartridge that is octagonal, the cell culture cartridge comprising: eight corners, including an inlet located at each corner; an outlet disposed centrally on a top surface of the cell culture cartridge; a bottom surface including one or more notches on a periphery of the bottom surface; one or more struts extending between said bottom surface and said top surface, said bottom surface and said top surface together at least in part defining a plurality of zones, each zone including one of said corners and one of said inlets, each zone tapering towards said outlet at said center of said top surface, each of said plurality of zones providing symmetrical fluid flow between its respective inlet and said outlet to avoid dead regions in flow within each of said plurality of zones due at least in part to a position of said inlet in each zone relative to said outlet; and one or more pumps operably associated with said cell culture cartridge A cell culture system comprising:

8. 8. The cell culture system of claim 7, wherein the inlet placement allows for symmetric fluid flow channels in the cell culture cartridge.

9. The cell culture system of claim 7 , wherein the cell culture cartridge includes a bottom surface constructed of a material to which cells adhere.

10. 8. The cell culture system of claim 7, further comprising one or more stopcocks operably connected to the cell culture cartridge.

11. 8. The cell culture system of claim 7, further comprising at least one fluid connector configured to fluidly couple the cell culture cartridge with a second container.

12. The cell culture system of claim 7, further comprising one or more sensors operably associated with the cell culture cartridge.

13. 13. The cell culture system of claim 12, wherein the one or more sensors measure one or more parameters selected from the group consisting of pH, dissolved oxygen, total biomass, cell diameter, glucose concentration, lactate concentration and cellular metabolite concentration.

14. further comprising a central processing unit, the central processing unit causing the system to receive first input data including a size of the cell culture cartridge; receiving second input data including a first concentration of a first cell type and a second concentration of a second cell type in one or more fluids to be introduced into the cell culture cartridge; and calculating a perfusion rate of a perfusion fluid to be introduced into the cell culture cartridge based on the first and second inputs, which maximizes the likelihood that the first cell type and the second cell type will contact each other within the cell culture cartridge. The cell culture system of claim 7 , which executes instructions.

15. 15. The system of claim 14, wherein the first cell type is a peripheral blood mononuclear cell and the second cell type is a dendritic cell.

16. 15. The system of claim 14, further comprising one or more pumps operably connected to one or more perfusion fluid reservoirs and operably connected to the central processing unit, wherein the central processing unit controls the perfusion rate of the perfusion fluid by controlling the one or more pumps.

17. 1. A method for culturing dendritic cells, comprising: Providing a cell culture cartridge that is octagonal, said cell culture cartridge comprising: eight corners, including an inlet located at each corner; an outlet disposed centrally on a top surface of the cell culture cartridge; a bottom surface including one or more notches on a periphery of the bottom surface; and one or more struts extending between said bottom surface and said top surface, said bottom surface and said top surface together at least in part defining a plurality of zones, each zone including one of said corners and one of said inlets, each zone tapering towards said outlet at said center of said top surface, each of said plurality of zones providing symmetrical fluid flow between its respective inlet and said outlet to avoid dead regions in flow within each of said plurality of zones due at least in part to a position of said inlet in each zone relative to said outlet. the steps of: seeding the cell culture cartridge with monocytic cells; and generating dendritic cells by incubating said monocytic cells in a cell culture cartridge and providing continuous perfusion of medium into said cell culture cartridge via an inlet and removing depleted medium via an outlet into a waste reservoir; A method comprising:

18. 20. The method of claim 17, further comprising the step of recovering the dendritic cells, wherein recovering the cells comprises cooling the cartridge.

19. 20. The method of claim 17, further comprising the step of transferring immature dendritic cells to a second cartridge, said second cartridge being smaller than said cell culture cartridge.

20. 20. The method of claim 19, wherein the immature dendritic cells are matured and subjected to antigen pulsing in the second cartridge.

21. The method of claim 17 , wherein fluid flows symmetrically through the cell culture cartridge.

Citation Information

Patent Citations

  • Monocyte separating material and monocyte and method for preparing dendritic cell utilizing the same

    JP2007312737A

  • Devices for high-throughput research on intercellular interactions

    JP2013538582A

  • Dendritic Cell Generator

    US20180171296A1

  • Cell culture chambers and methods of use thereof

    WO2018005521A2